FORM PTO-1390 (Modified) (REV 10-95) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER: 48418

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR): 09/091608

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB96/03209	23 December, 1996	21 December 1995

TITLE OF INVENTION
CELL ACTIVATION PROCESS AND REAGENTS THEREFOR

APPLICANT(S) FOR DO/EO/US
Bebbington, Christopher, R.; Lawson, Alastair, D., G.; Weir, Andrew, Neil, Charles and Finney, Helene, Margaret

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☒ has been transmitted by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ have been transmitted by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☐ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 18 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
    A **SECOND** or **SUBSEQUENT** preliminary amendment.
16. ☐ A substitute specification.
17. ☐ A change of power of attorney and/or address letter.
18. ☒ Certificate of Mailing by Express Mail
19. ☒ Other items or information:

Published PCT Application No. WO 97/23613
Form PCT/IB/308

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
	PCT/GB96/03209	48418

20. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☒	Search Report has been prepared by the EPO or JPO	**$930.00**
☐	International preliminary examination fee paid to USPTO (37 CFR 1.482)	**$720.00**
☐	No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))	**$790.00**
☐	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO	**$1,070.00**
☐	International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)	**$98.00**

ENTER APPROPRIATE BASIC FEE AMOUNT = **$930.00**

Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)). **$130.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	52 - 20 =	32	x $22.00	**$704.00**
Independent claims	3 - 3 =	0	x $82.00	**$0.00**
Multiple Dependent Claims **(check if applicable).**			☒	**$270.00**

TOTAL OF ABOVE CALCULATIONS = **$2,034.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) **(check if applicable).** ☐ **$0.00**

SUBTOTAL = **$2,034.00**

Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). + **$0.00**

TOTAL NATIONAL FEE = **$2,034.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐ **$0.00**

TOTAL FEES ENCLOSED = **$2,034.00**

Amount to be: refunded	$
charged	$

☒ A check in the amount of **$2,034.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. in the amount of to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **04-1105** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David G. Conlin, Esq.
Dike, Bronstein, Roberts & Cushman, LLP
130 Water Street
Boston, MA 02109

SIGNATURE

Peter J. Manus
NAME

26.766
REGISTRATION NUMBER

June 19, 1998
DATE

CELL ACTIVATION PROCESS AND REAGENTS THEREFOR

This invention relates to a process for activating cells, a DNA delivery system for achieving cell activation and the use of activated cells in medicine.

The natural T-cell receptor is a complex association of polypeptide chains comprising antigen binding, transmembrane and cytoplasmic components. Binding of antigen to the receptor in the correct context triggers a series of intracellular events leading to activation of the T-cell and for example destruction of the antigen presenting target cell. Before recognition of the antigen can take place, the antigen must be presented in association with MHC molecules.

It would be highly desirable if this requirement for MHC could be bypassed by engineering T-cells to become active on binding ligands other than a natural MHC-presented antigen. This would provide a means of avoiding the variability between individuals associated with MHC presentation and would also permit the targeting of more highly expressed surface antigens thereby increasing the efficacy of lymphocyte mediated therapy, for example in tumour therapy.

Chimeric receptors have been designed to target T-cells to cells expressing antigen on their cell surface. Such recombinant chimeric receptors include chimeras containing binding domains from antibodies and intracellular signalling domains from the T-cell receptor, termed 'T-bodies' [see for example Published International Patent Specifications Nos. WO 92/10591, WO 92/15322, WO 93/19163 and WO 95/02686].

The recombinant chimeric receptors described in the art are composed of a ligand binding component, a transmembrane component and a cytoplasmic component. It has been found however, that transfection of T-cells with these recombinant chimeric receptors does not result in acceptable levels of T-cell activation upon antigen binding unless the T-cell is also co-stimulated by, for example, treatment with high levels of

interleukin 2 [Il-2]. The need for co-stimulation makes the method suitable principally for *ex-vivo* treatment of patients. This is a lengthy and complicated procedure.

The present invention offers an alternative to the present *ex-vivo* approach in that it achieves improved *ex-vivo* activation without the need for addition of costimulating agents such as Il-2. It also advantageously provides successful *in-vivo* redirection and activation of T-cells, particularly in response to a single type of extracellular interaction.

Essentially the invention provides an effector cell which has been transformed with DNA coding for a chimeric receptor. The chimeric receptor contains two or more different signalling cytoplasmic components which are not naturally linked and which advantageously are chosen to act together cooperatively to produce improved activation of the cell. DNA coding for such recombinant chimeric receptors may be introduced into T-cells or other effector cells *in-vivo* and/or *ex-vivo*. Subsequent binding of an effector cell expressing one or more of these chimeric receptors to a target cell elicits signal transduction leading to activation of the effector cell in a process involving clustering or dimerisation of chimeric receptors or allosteric changes in the chimeric receptor or another mechanism for receptor-triggering.

Thus according to one aspect of the invention we provide a method of activating a cell as a result of one type of extracellular interaction between said first cell and a molecule associated with a second target cell characterised in that said first cell is provided with a DNA delivery system comprising DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling components, wherein said cytoplasmic components are not naturally linked, and at least one is derived from a membrane spanning polypeptide.

The DNA coding for the chimeric receptor(s) is arranged such that when it is expressed, and on the extracellular interaction between the cell and a second target cell, a signal is transduced via the cytoplasmic signalling components to two or more different intracellular signalling messengers.

This results in activation of the cell and elicits a biological response to the target cell. As used herein, cell activation means activation of one or more signal transduction pathways. This may be evidenced by an increase in cell proliferation; expression of cytokines with, for example pro or anti-inflammatory responses; stimulation of cytolytic activity, differentiation or other effector functions; antibody secretion; phagocytosis; tumour infiltration and/or increased adhesion.

The cytoplasmic signalling components are preferably selected such that they are capable of acting together cooperatively. They are "not naturally linked", which term is used herein to denote cytoplasmic signalling components which in nature are not connected to each other on a single polypeptide chain. Particularly useful signalling components include those described hereinafter in relation to other aspects of the invention.

In addition to the cytoplasmic signalling components each recombinant chimeric receptor preferably comprises a binding component capable of recognising a cell surface molecule on a target cell, and a transmembrane component. The DNA coding for these components will additionally code for a signal peptide to ensure that the chimeric receptor(s) once expressed will be directed to the cell surface membrane. All the components may be coded for by a single DNA coding sequence.

Alternatively, each cytoplasmic signalling component may be coded for by two or more separate DNA coding sequences. In this instance each DNA coding sequence may also code for a signal peptide, a transmembrane component and/or a binding component. The binding components may be different, but will generally all be capable of participating in the same type of extracellular event, for example by binding to the same molecule associated with the target cell. In one preference the binding components are the same.

In some of the applications described hereinafter, for example where the binding component is an antibody or an antibody fragment, the DNA coding for the chimeric receptor may comprise two separate DNA coding sequences, one sequence for example coding for part of the binding

component [in the case of an antibody for example a V_H component] linked to the signal peptide, transmembrane and cytoplasmic signalling component(s), and the second sequence coding for the remainder of the binding component [for example a V_L compoonent in the example given].

In order to activate a desired cell the DNA coding for the chimeric receptor will first need to be delivered to the cell. Thus according to a second aspect of the invention we provide a DNA delivery system comprising DNA in association with a carrier said DNA coding for a recombinant chimeric receptor capable of one type of extracellular interaction and comprising two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide.

In this aspect of the invention the chimeric receptor may be coded for by a single DNA coding sequence, coding in particular for the two or more different cytoplasmic signalling components. Thus in one preference the invention provides a DNA delivery system comprising DNA in association with a carrier said DNA coding for a recombinant chimeric receptor wherein said DNA codes in reading frame for:

i) a signal peptide component;
ii) a binding component capable of recognising a cell surface molecule on a target cell;
iii) a transmembrane component;
iv) two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide. and optionally
v) one or more spacer regions linking any two or more of said i) to iv) components.

The components of the recombinant chimeric receptor are operatively linked such that the signalling cytoplasmic components are functional in transducing a signal resulting in activation of one or more messenger

systems as a result of recognition of a cell surface molecule on a target cell by the binding component.

Two or more of the components may be linked by one or more spacer regions. The spacer regions may function to facilitate the components adopting the correct conformation for biological activity. The use of a spacer region to link the transmembrane component iii) and the binding component ii) is particularly advantageous.

The spacer regions may for example comprise up to 300 amino acids and preferably 20 to 100 amino acids and most preferably 25 to 50 amino acids.

Spacers may be derived from all or part of naturally occurring molecules such as from all or part of the extracellular region of CD8, CD4 or CD28; or all or part of an antibody constant region, including the hinge region. All or part of natural spacing components between functional parts of intracellular signalling molecules for example spacers between ITAMS (immunoreceptor tyrosine based activation motifs) may also be used. Alternatively the spacer may be a non-naturally occurring sequence.

The binding component ii) may be any molecule capable of interacting with cell surface molecules and may be chosen to recognise a surface marker expressed on cells associated with a disease state such as for example those associated with virally infected cells; bacterially infected cells; cancer cells, such as the bombesin receptor expressed on lung tumour cells, carcinoembryonic antigen, polymorphic epithelial mucin, and CD33; peptide hormones, adhesion molecules, inflammatory cells present in autoimmune disease, or a T-cell receptor or antigen giving rise to autoimmunity.

Suitable binding components for use in the chimeric receptors of the invention also include all or part of receptors associated with binding to cell surface associated molecules: the T-cell receptor; CD4; CD8; CD28; cytokine receptors e.g. an interleukin receptor, TNF receptor, or interferon receptor e.g. γ-IFN; receptors for colony stimulating factors e.g. GMCSF;

antibodies and antigen binding fragments thereof including for example Fab, Fab', $F(ab')_2$, single chain Fv, Fv, and V_H or V_L components which may be in association with C_H and C_L domains. The antibodies or fragments may be murine, human, chimeric or engineered human antibodies and fragments. As used herein the term engineered human antibody or fragment is intended to mean an antibody or fragment which has one or more CDR's and one or more framework residues derived from one antibody, e.g. a murine antibody embedded in an otherwise human framework. Such antibodies are well known and may be prepared by a number of methods for example as described in International Patent Specification No. WO91/09967.

Particularly useful binding components include Fab' fragments or, especially, single chain Fv fragments.

When the binding component is an antibody or antibody fragment other than a single chain Fv or V_H or V_L component which contains separate binding chains it will be necessary to include a second separate DNA coding sequence in the delivery system according to the invention to code for the second binding chain. In this instance the first DNA sequence containing the cytoplasmic signalling components and one chain of the antibody or fragment will be coexpressed with the second DNA sequence coding for a signal peptide and the second chain of the antibody or fragment so that assembly of the antibody binding component can occur.

Transmembrane components iii) may be derived from a wide variety of sources such as all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, a cytokine receptor, e.g. an interleukin receptor, TNF receptor, or interferon receptor, or a colony stimulating factor receptor e.g. GMCSF.

The binding and transmembrane components may be linked directly or, preferably, by a spacer region. The spacer region may be one or more of the regions described above. Where more than one region is present, for example two regions, these are preferably different regions, for example

an antibody hinge region linked to all or part of the extracellular region of CD28.

The spacer and transmembrane components are advantageously chosen such that they have free thiol groups thereby providing the chimeric receptor with multimerisation, particularly dimerisation capacity. Receptors of this type, especially dimers, are particularly preferred and include those which have CD28 components, the zeta chain of the natural T-cell receptor, and/or antibody hinge sequences.

The transmembrane component may or may not be naturally linked to the cytoplasmic component to which it is attached either directly or by means of a spacer.

The cytoplasmic signalling components iv) can for example transduce a signal which results in activation of one or more intracellular messenger systems. It is preferred that each of the cytoplasmic components activates a different messenger system. The intracellular messenger systems which may be activated either directly or indirectly include, for example, one or more kinase pathways such as those involving tyrosine kinase, PKC or MAP kinase; G-protein or phospholipase mediated pathways; calcium mediated pathways; and pathways involving synthesis of a cytokine such as an interleukin e.g. IL-2, including NFAT, and cAMP mediated pathways.

Examples of suitable cytoplasmic components iv) include, for example those derived from the T-cell receptor such as all or part of the zeta, eta or epsilon chain; CD28; the γ chain of a Fc receptor; or signalling components from a cytokine receptor e.g. interleukin, TNF and interferon receptors, a colony stimulating factor receptor e.g. GMCSF, a tyrosine kinase e.g. ZAP-70, fyn, lyk, Itk and syk; an adhesion molecule e.g. LFA-1 and LFA-2, B29, MB-1, CD3 delta, CD3 gamma, CD5 or CD2. The signalling cytoplasmic components are preferably ITAM containing cytoplasmic components

The cytoplasmic signalling components are preferably selected so that they act cooperatively. They may be in any orientation relative to one another. Particularly useful components include all or part of the signalling component of CD28 or the zeta chain of theT-cell receptor.

The signal component may be that naturally associated with the binding component or may be derived from other sources.

Examples of suitable signal peptide components i) include immunoglobulin signal sequences.

The signal component, binding component, transmembrane component, and cytoplasmic components are preferably derived from or based on human sequences.

Homologues of the individual components of the chimeric receptor may be used and the invention is to be understood to extend to such use. The term homologue as used herein with respect to a particular nucleotide or amino acid sequence coding for a component of the chimeric receptor represents a corresponding sequence in which one or more nucleotides or amino acids have been added, deleted, substituted or otherwise chemically modified provided always that the homologue retains substantially the same function as the particular component of the chimeric receptor. Homologues may be obtained by standard molecular biology and/or chemistry techniques e.g. by cDNA or gene cloning, or by use of oligonucleotide directed mutagenesis or oligonucleotide directed synthesis techniques or enzymatic cleavage or enzymatic filling in of gapped oligonucleotides.

Fragments of the individual components may also be used wherein one or more nucleotides has been deleted provided that the fragment retains substantially the same function as the starting component of the chimeric receptor.

The DNA for use in this and other aspects of the invention may be obtained from readily available DNA sources using standard molecular

biology and/or chemistry procedures, for example by use of oligonucleotide directed mutagenesis or oligonucleotide directed synthesis techniques, enzymatic cleavage or enzymatic filling in of gapped oligonucleotides. Such techniques are described by Maniatis *et al* in Molecular Cloning, Cold Spring Harbor Laboratory, New York 1989, and in particular in the Examples hereinafter.

The carrier for use in the DNA delivery systems according to the invention may be a vector or other carrier suitable for introduction of the DNA *ex-vivo* or *in-vivo* into target cells and/or target host cells. Examples of suitable vectors include viral vectors such as retroviruses, adenoviruses, adenoassociated viruses, EBV, and HSV, and non-viral vectors, such as liposomal vectors and vectors based on DNA condensing agents. Alternatively the carrier may be an antibody. Where appropriate, the vector may additionally include promoter/regulatory sequences and/or replication functions from viruses such as retrovirus LTRs, AAV repeats, SV40 and hCMV promoters and/or enhancers, splicing and polyadenylation signals; EBV and BK virus replication functions. Tissue specific regulatory sequences such as the TCR-α promoter, E-selectin promoter and the CD2 promoter and locus control region may also be used.

Where two or more DNA molecules are used in the DNA delivery system they may be incorporated into the same or different carriers as described above.

For *ex-vivo* use, the DNA delivery system of the invention may be introduced into effector cells removed from the target host using methods well known in the art e.g. transfection, transduction, biolistics, protoplast fusion, calcium phosphate precipitated DNA transformation, electroporation, cationic lipofection, or targeted liposomes. The effector cells are then reintroduced into the host using standard techniques.

A wide variety of target hosts may be employed according to the present invention such as, for example, mammals and, especially, humans.

Examples of suitable effector cells include cells associated with the immune system such as lymphocytes e.g. cytotoxic T-lymphocytes, tumour infiltrating lymphocytes, natural killer cells, neutrophils, basophils or T-helper cells; dendritic cells, B-cells, haemoatopaietic stem cells, macrophages, monocytes or NK cells. The use of cytotoxic T-lymphocytes is especially preferred.

The DNA delivery system according to the invention is particularly suitable for *in vivo* administration. It may be in one preferred example in the form of a targeted delivery system in which the carrier is capable of directing the DNA to a desired effector cell. Particular examples of such targeted delivery systems include targeted-naked DNA, targeted liposomes encapsulating and/or complexed with the DNA. targeted retroviral systems and targeted condensed DNA such as protamine and polylysine condensed DNA.

Targeting systems are well known in the art and include using, for example, antibodies or fragments thereof against cell surface antigens expressed on target cells *in vivo* such as CD8; CD16; CD4; CD3; selectins e.g. E-selectin; CD5; CD7; CD34; activation antigens e.g. CD69 and IL-2R. Alternatively, other receptor - ligand interactions can be used for targeting e.g. CD4 to target $HIV_{gp}160$ - expressing target cells.

In general the use of antibody targeted DNA is preferred, particularly antibody targeted naked DNA, antibody targeted condensed DNA and especially antibody targeted liposomes. Particular types of liposomes which may be used include for example pH-sensitive liposomes where linkers cleaved at low pH may be used to link the antibody to the liposome. Cationic liposomes which fuse with the cell membrane and deliver the recombinant chimeric receptor DNA according to the invention directly into the cytoplasm may also be used. Liposomes for use in the invention may also have hydrophilic groups attached to their surface to increase their circulating half-life such as for example polyethylene glycol polymers. There are many examples in the art of suitable groups for attaching to liposomes or other carriers; see for example International Patent

91/05546, WO 93/19738, WO 94/20073 and WO 94/22429. The antibody or other targeting molecule may be linked to the DNA, condensed DNA or liposome using conventional readily available linking groups and reactive functional groups in the antibody e.g. thiols, or amines and the like, and in the DNA or DNA containing materials.

Non-targeted delivery systems may also be used and in these targeted expression of the DNA is advantageous. Targeted expression of the DNA may be achieved for example by using T-cell specific promoter systems such as the zeta promoter and CD2 promoter and locus control region, and the perforin promoter.

The aspect of the invention described above advantageously utilises a single DNA sequence to code for the chimeric receptor. It will be appreciated however that the invention may be extended to DNA delivery systems in which the chimeric receptor is coded for by two or more separate DNA coding sequences. Thus in one example, a first and second separate DNA coding sequence may be present in the delivery system each of which codes for components i) to iv) and optionally v) in the same reading frame as described above but which differ from each other in that the cytoplasmic signalling component iv) is not the same. The two DNA coding sequences may each code for more than one signalling component providing that at least one component on the first DNA is different to any other signalling component on the second DNA. As above, the signalling components are advantageously selected to act cooperatively and the remaining components may be any of those previously described for the single DNA embodiment. The binding component iv) coded for by the first DNA will preferably be the same as that coded for by the second DNA. Advantageously the binding component coded by the first DNA will be separated from the transmembrane component by a different spacer region to that coded by the second DNA.

The delivery system may be used *ex vivo* and in a further aspect the invention provides effector cells transfected with a DNA delivery system according to the invention. The effector cells may be any of those

previously described above which are suitable for *ex vivo* use and are preferably T-cells most preferably cytotoxic T-cells.

The DNA delivery system may take the form of a pharmaceutical composition. It may be a therapeutic or diagnostic composition and may take any suitable form suitable for administration. Preferably it will be in a form suitable for parenteral administration e.g. by injection or infusion, for example by bolus injection or continuous infusion. Where the composition is for injection or infusion, it may take the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it may contain formulatory agents such as suspending, preservative, stabilising and/or dispersing agents. Alternatively, the composition may be in dry form, for reconstitution before use with an appropriate sterile liquid.

If the composition is suitable for oral administration the formulation may contain, in addition to the active ingredient, additives such as: starch - e.g. potato, maize or wheat starch or cellulose - or starch derivatives such as microcrystalline cellulose; silica; various sugars such as lactose; magnesium carbonate and/or calcium phosphate. It is desirable that, if the formulation is for oral administration it will be well tolerated by the patient's digestive system. To this end, it may be desirable to include in the formulation mucus formers and resins. It may also be desirable to improve tolerance by formulating the compositions in a capsule which is insoluble in the gastric juices. It may also be preferable to include the composition in a controlled release formulation.

The DNA delivery system according to the invention is of use in medicine and the invention extends to a method of treatment of a human or animal subject, the method comprising administering to the subject an effective amount of a DNA delivery system described above. The exact amount to be used will depend on the ages and condition of the patient, the nature of the disease or disorder and the route of administration, but may be determined using conventional means, for example by extrapolation of animal experiment derived data. In particular, for *ex vivo* use the number of transfected effector cells required may be established by *ex vivo* transfection and re-introduction into an animal model of a range of effector

cell numbers. Similarly the quantity of DNA required for *in vivo* use may be established in animals using a range of DNA concentrations.

The DNA delivery system according to the invention may be useful in the treatment of a number of diseases or disorders. Such diseases or disorders may include those described under the general headings of infectious diseases, e.g. HIV infection; inflammatory disease/autoimmunity e.g. rheumatoid arthritis, osteoarthritis, inflammatory bowel disease; cancer; allergic/atopic diseases e.g. asthma, eczema; congenital e.g. cystic fibrosis, sickle cell anaemia; dermatologic, e.g. psoriasis; neurologic, e.g. multiple sclerosis; transplants e.g. organ transplant rejection, graft-versus-host disease; metabolic/idiopathic disease e.g. diabetes.

DNA coding for a chimeric receptor as described herein also forms a feature of the invention, particularly for use in a delivery system described herein.

The invention is further illustrated in the following non-limiting Examples and Figures in which:

Figure 1 shows: diagrammatic representation of recombinant chimeric receptor constructs cloned into pBluescript SK+

Figure 2 shows: diagrammatic representation of recombinant chimeric receptor constructs cloned into pBluescript SK+

Figure 3 shows: oligonucleotide sequences for recombinant chimeric receptor construction

Figure 4 shows: nucleotide and amino acid sequence of an hCTMO1/CD8/zeta recombinant chimeric receptor

Figure 5 shows: nucleotide and amino acid sequence of an hCTMO1/CD8/zeta-CD28 recombinant chimeric receptor fusion

Figure 6 shows: nucleotide and amino acid sequence of an hCTMO1/CD8/CD28 recombinant chimeric receptor

Figure 7 shows: nucleotide and amino acid sequence of an CTMO1/G1/zeta recombinant chimeric receptor

Figure 8 shows: nucleotide and amino acid sequence of an hCTMO1/G1/zeta-CD28 recombinant chimeric receptor fusion

Figure 9 shows: nucleotide and amino acid sequence of an hCTMO1/h/CD28 recombinant chimeric receptor

Figure 10 shows: histogram representation of IL2 production by cell lines TB3.2, 3.13 and 3.24 when stimulated with an anti-idiotypic antibody alone or in combination with an anti-CD28 antibody

Figure 11 shows: histogram representation of the production of IL2 by cell line TB3.13 when stimulated with antigen expressing tumour cells, shown with and without co-stimulation using an anti-CD28 antibody.

Figure 12 shows: histogram representation of IL-2 production by HGT1.2 and HGT1.4 in response to various stimuli

Figure 13 shows: histogram representation of IL-2 production by HGT2.4 incubated with various combinations of antibodies.

Figure 14 shows: schematic representation of recombinant chimeric receptor constructs.

Figure 15 shows: schematic representation of recombinant chimeric receptor constructs

Figure 16 shows: schematic representation of recombinant chimeric receptor constructs.

Figure 17 shows: schematic representation of recombinant chimeric receptor constructs

Figure 18 shows: histogram representation of levels of expression of CD28 chimeras in Jurkat cells

Figure 19 shows: histogram representation of IL-2 production by Jurkat cells expressing two different chimeric receptors in response to target cells.

Figure 20 shows: Graph showing Cytolysis of target cells by CD8+ve human CTL cells infected with recombinant adenoviruses

EXAMPLE 1

Construction of chimeric receptor genes

Each component of the chimeric receptor constructs was either PCR cloned or PCR assembled by standard techniques (PCR Protocols, Innis et al, 1990, Academic Press inc.) and sub-cloned in a cassette format into pBluescript SK+ (Stratagene), see figure 1, 2, 2b and 2c. Oligonucleotides are described in Figure 3.

1. **Single chain Fv cassettes**

hCTMO1

An scFv from the engineered human CTMO1 antibody was constructed as follows. Leader sequence and hCTMO1 VI was PCR cloned from plasmid pAL 47 (International Patent Specification No. WO 93/06231) with oligos R6490 and R6516 (Oligo sequences are shown in Figure 3). R6490 introduces 5' Not I and Hind III sites and R6516 forms part of the $(Gly4Ser)_5$ linker. hCTMO1 Vh was PCR cloned from plasmid pAL 52 (WO 93/06231) with oligos R6515 (forms part of linker) and R6514 (introduces 3' Spe I site. Leader / VI and Vh fragments were then PCR spliced together and the PCR product was restricted with Not I and Spe I and sub-cloned into pBluescript SK+.

hP67.6

An scFv from another engineered human antibody, hP67.6, engineered according to WO91/09967, was similarly prepared and subcloned into pBluescript SK+.

2. **CD8 hinge spacer cassette**

The CD8 hinge spacer for hCTMO1 TCR Zeta chimeric receptor and hCTMO1 TCR Zeta-CD28 fusion chimeric receptor (which includes a small part of 5' Zeta) was PCR assembled using overlapping oligos: R6494,R6495,R6496 and R6497. The CD8 hinge spacer for hCTMO1 CD28 chimeric receptor was PCR assembled using overlapping oligos:

R6494,R6495,R6496 and R6506. Both PCR products were restricted with Spe I and BamH I and sub-cloned into pBluescript SK+.

3. **Human TCR Zeta cassette**

Human Zeta transmembrane and intracellular components were PCR cloned from human leukocyte cDNA (Clonetech) with oligos R6488 (introducing a 5' BamH I site) and R6489 (introducing a 3' EcoR I site). PCR product was restricted with BamH I and EcoR I and sub-cloned into pBluescript SK+.

4. **Human CD28 cassette**

Human CD28 transmembrane and intracellular components were PCR cloned from human leukocyte cDNA (Clonetech) with oligos P3240 (introducing a 5' BamH I site) and P3241 (introducing a 3' EcoR I site). PCR product was restricted with BamH I and EcoR I and sub-cloned into pBluescript SK+.

5. **Hinge-CD28 cassette**

Human CD28 extracellular, transmembrane and intracellular components were PCR cloned from human leukocyte cDNA (Clonetech) with oligos S0146 (introducing a 5' Spe I site) and P3241 (introducing a 3' EcoR I site). S0146 also constitutes residues 234 to 243 of human IgG1 hinge. The product of the PCR reaction was digested with restriction enzyme Spe1 and EcoR1 and sub-cloned into pBluescriptSK+.

6. **Zeta-CD28 fusion cassette**

The 3' end of Zeta, starting at a naturally occuring Sty I site and the intracellular component of human CD28 were PCR assembled such that the Zeta stop codon was removed and an inframe fusion protein would be translated. PCR assembly carried out with overlapping oligos: P3301, P3302, P3303, P3304, P3305 and P3306. PCR product was restricted with Sty I and EcoR I and sub-cloned into pBluescriptSK+ containing the hCTMO1 TCR Zeta chimeric receptor construct, replacing the 3' end of Zeta.

7. **Human IgG1 spacer cassette**

Human IgG1 hinge, CH2 and CH3 were PCR cloned from IgG1 cDNA clone (A. Popplewell) with oligos S0060 (introducing a 5' Spe I site) and S0061 (introducing residues L, D, P, and K constituting a 3' BamH I site). PCR product was restricted with Spe I and BamH I and sub-cloned into pBluescriptSK+.

8. **h.28 spacer cassette**

Human IgG1 hinge and part of human CD28 extracellular component were PCR cloned from a scFv/h/CD28 plasmid with oligos T4057 and T4058. T4057 introduces a 5' Spe I site and T4058 introduces residues L, D, P, and K constituting a 3' BamH I site. PCR product was restricted with Spe I and BamH I and sub-cloned into pBluescriptSK+.

9. **CD28-Zeta fusion cassette**

Human CD28 transmembrane and intracellular componenets were PCR cloned from a scFv/h/CD28 plasmid with oligos T7145 and T4060. T7145 introduces residues L, D, P, and K constituting a 3' BamH I site. T4060 comprises a 3' overhang compatable with the 5' end of human Zeta intracellular component.

Human Zeta intracellular component was PCR cloned from a scFv/G1/Zeta plasmid with oligos T4387 and S4700. T4387 comprises a 5' overhang compatable with the 3' end of hunan CD28 intracellular component. S4700 introduces a 3' EcoR I site.

CD28 transmembrane and intracellular components were then PCR spliced to Zeta intracellular component with oligos T7145 andS4700.

PCR product was restricted with BamH I and EcoR I and sub-cloned into pBluescriptSK+.

10. **CD28-Zeta-CD28 fusion cassette**

A Pst I restriction site in human Zeta was used to subclone the 3' end of Zeta intracellular component and the CD28 intracellular component on a Pst I to EcoR I fragment ifrom the Zeta-CD28 fusion cassette into the CD28-Zeta fusion cassette, replacing the 3' end of Zeta. This generates a CD28-Zeta-CD28 fusion cassette with a 5' BamH I site and 3' EcoR I site.

All of the above cassettes were completely sequenced (Applied Biosystems, Taq DyeDeoxy Terminator Cycle Sequencing, Part Number 901497) in pBluescriptSK+ prior to cloning into the expression vectors.

These cassettes were assemled to construct chimeric receptors with the specificity of the engineered human antibodies hCTMO1, directed against human polymorphic epithelial mucin (PEM) or hP67.6, directed against human CD33, by assembling the appropriate cassettes using standard molecular biology techniques. The following chimeric receptors were constructed; see Table 2 and Figures 14 - 17 in which potential di-sulphide bonds are indicated by a horizontal line between the two sub-units (not all di-sulphide bonds may form in 100% of the molecules).

1) **scFv / CD8 / Zeta Chimeric Receptor (Figure 14)**

The scFv / CD8 / Zeta chimeric receptor consists of a single chain Fv (scFv) linked to an extracellular spacer in the form of part of human CD8 hinge, linked to the extracellular, transmembrane and intracellular components of the human T-cell receptor Zeta chain (TCR).

The scFv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 98 to 142 of the hinge region of human CD8 (Zamoyska *et al* : Cell 43,153-163, 1985).This is linked to residues 6 to 142 of human TCR Zeta comprising extracellular (part), transmembrane and intracellular regions (Weissman *et al* : PNAS 85, 9709-9713, 1988. Moingeon *et al:*Eur. J. Immunol. 20, 1741-1745, 1990).

2) **scFv / CD8 / CD28 Chimeric Receptor (Figure 14)**

The CD8 hinge/CD28 chimeric receptor consists of a scFv linked to an extracellular spacer in the form of part of human CD8 hinge, linked to the transmembrane and intracellular component of human CD28.

The scFv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$

linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 98 to 142 of the hinge region of human CD8 (Zamoyska *et al* : Cell 43 153-163, 1985). This is linked to residues 132 to 202 of human CD28 comprising the transmembrane and intracellular components (Aruffo & Seed : PNAS 84, 8573-8577).

3) **scFv /CD8 / Zeta-CD28 Fusion Chimeric Receptor (Figure 14)**

The scFv /CD8 / Zeta-CD28 Fusion chimeric receptor consists of a single chain Fv linked to an extracellular spacer in the form of part of human CD8 hinge, linked to the extracellular, transmembrane and intracellular components of human TCR Zeta fused to the intracellular component of human CD28.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extra cellular spacer consists of residues 98 to 142 of the hinge region of human CD8 (Zamoyska *et al* : Cell, 43,153-163, 1985). This is linked to residues 6 to 142 of human TCR Zeta comprising extracellular (part), transmembrane and intracellular components (Weissman *et al* : PNAS 85,9709-9713, 1988 Moingeon *et al:*Eur. J. Immunol. 20, 1741-1745, 1990).

This is linked to residues 162 to 202 comprising the intracellular component of human CD28.

4) **scFv / G1 / Zeta Chimeric Receptor (Figure 15)**

The scFv / G1 / Zeta chimeric receptor consists of a single chain Fv linked to an extracellular spacer comprising human IgG 1 hinge, CH2 and CH3, linked to the transmembrane and intracellular regions of human TCR Zeta.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge, 244 to 360 of CH2 and 361 to 478 of

CH3 (Kabat *et al* Sequences of proteins of immunological interest, 1987). This is linked to residues 6 to 142 of human TCR Zeta comprising extracellular (part), transmembrane and intracellular regions (Weissman *et al* : PNAS 85 ,9709-9713, 1988. Moingeon *et al:*Eur. J. Immunol. 20, 1741-1745, 1990).

5) **scFv / G1 / Zeta-CD28 fusion Chimeric Receptor (Figure 15)**

The scFv / G1 / Zeta chimeric receptor consists of a single chain Fv linked to an extracellular spacer comprising human IgG 1 hinge, CH2 and CH3, linked to the transmembrane and intracellular regions of human Zeta fused to the intracellular region of human CD28.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge, 244 to 360 of CH2 and 361 to 478 of CH3 (Kabat *et al* Sequences of proteins of immunological interest, 1987). This is linked to residues 6 to 142 of human TCR Zeta comprising extracellular (part), transmembrane and intracellular regions (Weissman *et al* : PNAS 85 ,9709-9713, 1988. Moingeon *et al:*Eur. J. Immunol. 20, 1741-1745, 1990).

This is linked to residues 162 to 202 comprising the intracellular component of human CD28 (Aruffo & Seed : PNAS 84, 8573-8577).

6) **scFv / h / CD28 Chimeric Receptor (Figure 15)**

The scFv / h / CD28 chimeric receptor consists of a single chain Fv linked to an extracellular spacer consisting of human IgG1 hinge and part of the extracellular region of human CD28, linked to the transmembrane and intracellular regions of human CD28.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge and residues 118 to 134 of human CD28.

This is linked to residues 135 to 202 of human CD28 comprising the transmembrane and intracellular regions (Aruffo & Seed : PNAS 84, 8573-8577).

7) **scFv / G1 / CD28 Chimeric Receptor (Figure 16)**

The scFv / G1 / Zeta chimeric receptor consists of a single chain Fv linked to an extra cellular spacer comprising human IgG 1 hinge, CH2 and CH3, linked to the transmembrane and intracellular regions of human CD28.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge, 244 to 360 of CH2 and 361 to 478 of CH3 (Kabat *et al* Sequences of proteins of immunological interest, 1987). This is linked via residues L, D, P and K to residues 135 to 202 comprising the transmembrane and intracellular components of human CD28 (Aruffo & Seed : PNAS 84, 8573-8577).

8) **scFv / G1 / CD28 -Zeta fusion Chimeric Receptor (Figure 16)**

The scFv / G1 / Zeta chimeric receptor consists of a single chain Fv linked to an extracellular spacer comprising human IgG 1 hinge, CH2 and CH3, linked to the transmembrane and intracellular regions of human CD28 fused to the intracellular region of human Zeta.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge, 244 to 360 of CH2 and 361 to 478 of CH3 (Kabat *et al* Sequences of proteins of immunological interest, 1987). This is linked via residues L, D, P and K to residues 135 to 202 comprising the transmembrane and intracellular components of human CD28.

This is linked to residues 31 to 142 of human TCR Zeta, the intracellular region (Weissman *et al* : PNAS 85 ,9709-9713, 1988. Moingeon *et al:Eur.* J. Immunol. 20, 1741-1745, 1990).

9) **scFv / G1 / CD28 -Zeta -CD28 fusion Chimeric Receptor (Figure 16)**

The scFv / G1 / Zeta chimeric receptor consists of a single chain Fv linked to an extracellular spacer comprising human IgG 1 hinge, CH2 and CH3, linked to the transmembrane and intracellular regions of human CD28 fused to the intracellular region of human Zeta fused to the intracellular region of CD28.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge, 244 to 360 of CH2 and 361 to 478 of CH3 (Kabat *et al* Sequences of proteins of immunological interest, 1987). This is linked via residues L, D, P and K to residues 135 to 202 comprising the transmembrane and intracellular components of human CD28.
This is linked to residues 31 to 142 of human TCR Zeta, the intracellular region (Weissman *et al* : PNAS 85 ,9709-9713, 1988. Moingeon *et al:*Eur. J. Immunol. 20, 1741-1745, 1990).
This is linked to residues 162 to 202 comprising the intracellular component of human CD28.

10) **scFv / h.28 / Zeta Chimeric Receptor (Figure 17)**

The scFv / h / CD28 chimeric receptor consists of a single chain Fv linked to an extracellular spacer consisting of human IgG1 hinge, part of the extracellular region of human CD28 and 4 amino acid residues, linked to the transmembrane and intracellular regions of human TCR Zeta.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge and residues 118 to 134 of human CD28. This is linked via residues L, D, P and K to residues 10 to 142 of human TCR Zeta comprising the transmembrane and the intracellular region

(Weissman *et al* : PNAS 85 ,9709-9713, 1988. Moingeon *et al:*Eur. J. Immunol. 20, 1741-1745, 1990).

11) **scFv / h.28 / Zeta-CD28 fusion Chimeric Receptor (Figure 17)**

The scFv / h / CD28 chimeric receptor consists of a single chain Fv linked to an extracellular spacer consisting of human IgG1 hinge, part of the extracellular region of human CD28 and 4 amino acid residues, linked to the transmembrane and intracellular regions of human Zeta fused to the intracellular region of human CD28.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge and residues 118 to 134 of human CD28. This is linked via residues L, D, P and K to residues 10 to 142 of human TCR Zeta comprising transmembrane and intracellular regions (Weissman *et al* : PNAS 85 ,9709-9713, 1988. Moingeon *et al:*Eur. J. Immunol. 20, 1741-1745, 1990).
This is linked to residues 162 to 202 comprising the intracellular component of human CD28.

12) **scFv / h.28 / CD28-Zeta fusion Chimeric Receptor (Figure 17)**

The scFv / h / CD28 chimeric receptor consists of a single chain Fv linked to an extracellular spacer consisting of human IgG1 hinge, part of the extracellular region of human CD28 and 4 amino acid residues, linked to the transmembrane and intracellular regions of human CD28 fused to the intracellular region of human Zeta.

The single chain Fv consists of the leader sequence and variable component of the light chain of the engineered human antibody linked via a $(Gly_4Ser)_5$ linker to the variable component of the heavy chain of the engineered human antibody. The extracellular spacer consists of residues 234 to 243 of human IgG1 hinge and residues 118 to 134 of human CD28. This is linked via residues L, D, P and K to residues 135 to 202 comprising the transmembrane and intracellular components of human CD28.

This is linked to residues 31 to 142 of human TCR Zeta, the intracellular region (Weissman *et al* : PNAS 85 ,9709-9713, 1988. Moingeon *et al:Eur.* J. Immunol. 20, 1741-1745, 1990).

Table 1 shows a number of preferred recombinant chimeric receptors which may be made in an analogous way by following the above teaching and methods.

Table 2 gives details of the chimeric receptor constructs and cell line nomenclature used.

EXAMPLE 2

Analysis of hCTMO1-chimeric receptor constructs expressed in Jurkat cells

Chimeric receptor constructs were sub-cloned from pBluescriptSK+ into the expression vectors pEE6hCMV.ne and pEE6hCMV.gpt (Bebbington (1991), Methods 2, 136-145) on a Hind III to EcoR I restriction fragment. The hCTMO1/CD8/ Zeta chimeric receptor construct was cloned into pEE6hCMVne and the hCTMO1 / CD8 /CD28 and hCTMO1 Zeta-CD28 fusion chimeric receptor constructs were cloned into pEE6hCMVgpt.

Plasmids were linearised and transfected into Jurkat E6.1 cells (ECACC) by electroporation using a Bio-Rad Gene Pulser using the method of Rigley *et al* (J. Immunol. (1995) 154, 1136-1145). Chimeric - receptor expressing colonies were selected in media either containg the drug G418 (2 mg/ml) for Neo vectors or Mycophenolic acid for Gpt vectors as described (Rigley et al ibid.). After approximately four weeks colonies were visible. Colonies were screened by analysis of surface expression of single chain Fv.

Antibodies

Anti-idiotype antibodies are purified antisera from rabbits immunised with hCTMO1. Anti-Id antibodies were purified initially on Protein A-Sepharose, absorbed out against human IgG-Sepharose and finally affinity purified on hCTMO1. OKT3 recognises an extracellular compononent of human CD3 ε (ATCC). Anti-CD28 used in these

experiments was a rat IgG2b monoclonal antibody (clone YTH 913.12) directed against the extracellular component of human CD28 (Cymbus Bioscience). FITC labelled donkey anti-rabbit Ig recognises rabbit heavy and light chains (Jackson Research Laboratories).

Analysis of surface expression of scFv

Approximately $5X10^5$ cells were stained with saturating concentrations of anti-idiotype (10µg/ml), then incubated with fluorescein-conjugated donkey anti-rabbit antibody. Fluorescence was analysed by a FACScan cytometer (Beckton Dickinson).

Anti-Id stimulation

1 X 10^6 Jurkat transfectants were incubated in a 96 well plate (Nunc) previously coated with / without a saturating concentration of anti-idiotype antibody at 37°C / 5% CO_2 in non-selective media. Additional stimuli of anti-CD28 and OKT3 were added in solution to a final concentration of 5µg/mL. After 18 to 20 hours cells were centrifuged and supernatant assayed for human IL-2 (Quantikine kit, R & D Systems).

Antigen expressing cell stimulation

1 X 10^6 Jurkat transfectants were incubated with 1 X 10^5 MCF-7 cells (P.E.M. antigen expressing) in a 96 well plate (Falcon) overnight at 37°C / 5% CO_2.

Additional stimulus of anti-CD28 was added in solution to a final concentration of 5µg/mL. After 18 to 20 hours cells were centrifuged and supernatant assayed for human IL-2 (Quantikine kit, R & D Systems).

RESULTS

Cross-linking the T-cell receptor with anti-CD3 antibodies can be used to stimulate human T-cell lines such as Jurkat E6.1 to produce cytokines including IL-2. The expression of IL-2 can be further enhanced by co-stimulation by means of antibodies to the CD28 cell surface molecule in this cell line. This therefore provides a convenient model system to

evaluate chimeric receptors for the ability to deliver signals which are co-stimulatory for T-cell activation.

1. **Enhancement of IL2 production by a Jurkat E6.1 cell line transfected with an hCTM01 scFv-CD8- TCR ζ chimeric receptor (plasmid pTB3 in response to antigen or anti-idiotype antibody by co-stimulation with an anti-CD28 antibody.**

The cell lines TB 3.2, 3.13 and 3.24 were stable cell lines derived from Jurkat E6.1 transfected with CTM01hscFv/CD8/Zeta. Figure 10 shows IL2 production by these cell lines when stimulated with an anti-CTMO1 idiotypic antibody alone or in combination with an anti-CD28 antibody. In each case the co-stimulation with anti CD-28 results in a greater than 2-fold stimulation of IL2 production compared to stimulation with anti-CTM01 idiotype antibody alone. Incubation of these cell lines with anti-CD28 alone did not result in stimulation of IL2.

Figure 11 shows the production of IL2 by one of the above cell lines (TB 3.13) when stimulated with antigen expressing tumour cells. As in figure 10 this is shown with and without co-stimulation using anti-CD28 antibody and indicates that co-stimulation can enhance IL-2 production when stimulation of the chimeric receptor is mediated by antigen.

2. **Construction and testing of a chimeric receptor designed to generate a response analogous to CD28 stimulation on interaction with the extracellular scfv component.**

Having established that co-stimulation via the CD28 molecule could result in enhancement of the response of a T cell transfectant to a tumour associated antigen a chimeric receptor incorporating the CD28 transmembrane and cytoplasmic components was constructed. This hCTM01/CD8/CD28 chimeric receptor (pHMF332) (HGT1) was transfected into Jurkat E6.1 cells to generate stable cell lines. Two of these lines HGT 1.2 and 1.4 were incubated in the presence of various combinations of stimulating antibodies as shown in figure 12 (see materials and methods for experimental procedure), and anti-idiotypic antibody was used to stimulate the chimeric receptor.

Incubation of the cell lines shown with an anti-CD3 antibody resulted in a low level of IL2 production. This stimulation could be enhanced by co-stimulating with an anti-CD28 antibody (column 5 figs. 12a and 12b).

Incubation with the anti-CD28 alone as expected did not result in IL2 production.

Similarly incubation with the anti-idiotypic antibody alone (stimulating the chimeric CD28 receptor) resulted in no IL2 production. However, by analogy with the combined anti-CD3 and anti-CD28 stimulation, incubation with anti-CD3 and anti-idiotype resulted in IL2 production enhanced over CD3 stimulation alone. This demonstrates that a chimeric receptor could be constructed that responds via stimulation of extracellular scFv to generate an intracellular signal capable of costimulating CD3 mediated activation.

3. **Provision of both primary and accessory stimulation in the same effector cell.**

In order to provide both primary (for example TCR ζ mediated) and co-stimulatory (for example CD28 mediated) activation of the effector cell via interaction of a chimeric receptor with a defined ligand or antigen a fusion receptor incorporating two different signalling components was constructed. This chimeric receptor hCTM01/CD8/TCRZeta-CD28 (pHMF334) was transfected into Jurkat E6.1 cells and stable lines selected. One of these lines (HGT 2.4) was incubated with various combinations of antibodies and IL2 production measured (see Fig. 13).

The anti-CD3 and anti-CD28 antibodies individually and in combination resulted in a similar relative stimulation of IL2 production to that seen with the other transfected cell lines. However, with the construct HGT2 the anti-idiotype antibody alone resulted in a level of IL2 production greater than achieved with the combined anti-CD3 and anti-CD28 antibodies. Furthermore, the stimulation achieved with the single anti-idiotypic interaction could not be enhanced by further co-stimulation with anti-CD3, anti-CD28 or combinations of these.

EXAMPLE 3

Analysis of single gene hP67.6-chimeric receptor constructs expressed in Jurkat cells

In order to confirm the results obtained with the hCTMO1 fusion receptor for a different antibody scFv, and to evaluate additional fusion receptors, a number of different chimeras based on the hP67.6 scFv were introduced into Jurkat cells.

Chimeric receptor constructs hP67.6 / G1 / Zeta (HGT16), hP67.6 / G1 / Zeta-CD28 (HGT17), hP67.6 / G1 /CD28-Zeta (HGT21), hP67.6 / G1 /CD28-Zeta-CD28 HGT26), hP67.6 /h.28 / Zeta-CD28 (HGT20) and hP67.6 /h.28 / CD28-Zeta (HGT22) chimeric receptor constructs were sub-cloned from pBluescriptSK+ into the expression vector pEE6hCMV.ne as described in Example 2. Expression plasmids were transfected into Jurkat E6.1 and permanent cell lines expressing chimeric receptors on their cell surfaces were identified as described above (Example 2) but using a purified rabbit anti-p67.6 idiotye antiserum prepared as described for hCTMO1 anti-idiotype. Alternatively, cells were stained with purified recombinant CD33 extracellular domain conjugated to FITC (10 µg/ml) and analysed directly on the cytometer.

Western blot analysis was carried out on representative clones for each construct to confirm that chimeric recptors of the expected size were expressed. Approximately 10^7 cells were lysed in lysis buffer (1% NP40,150mM NaCl, 10mM NaF, 0.4mM EDTA, 1mM Na vanadate, 1 mg/ml Pefabloc, 10 µg/ml Pepstatin, 10 µg/ml Leupeptin, 20 µg/ml Aprotinin) and samples subjected to SDS-PAGE with or without reduction of cystine residues with β-mercaptoethanol. Western blots were probed with rabbit ant-P67.6 idiotype followed by horseradish - peroxidase (HRP) conjugated donkey anti-rabbit Ig or HRP-conjugated rabbit anti-human Fc antisera according to standard techniques.

A comparison of the apparent molecular weights of the chimeric receptors in reduced and non-reduced samples indicated that the zeta-chain chimera in cell line HGT16.1 and the fusion receptor in HGT17.39 were present as di-sulphide linked homodimers. The CD28 chimera in HGT14.1

is present as approximately 50% disulphide-linked homodimers and approximately 50% of the molecules are not disulphide linked. At least 50% of molecules are disulphide - linked in the case of the fusion receptors in HGT20, HGT21 and HGT22 cell lines.

A panel of independent transfectant clones for each construct were analysed for IL-2 production in response to cells which express CD33 (HL60 cells) or are CD33 negative (eg Jurkat E6.1). It is important to analyse a number of clones expressing each construct since individual clones vary substantially in the level of expression of chimeric recptor. Moreover, even clones expressing similar levels of receptor show different capacities to produce IL-2. Each transfectant was mixed with an equal number of target cells (eg 10^5 cells of each cell type per well of a 96-well plate) and co-cultured for approximately 20 h. The concentration of IL-2 in the supernatant was then determined using a Quantikine human IL-2 ELISA (R&D Systems).

Cell lines containing construct HGT 16 produce levels of IL-2 in response to HL60 cells of up to approximately 200 pg/ml and do not produce detectable IL-2 when stimulated with CD33 - negative cells. Cell lines expressing fusion receptors HGT17, 20, 21, 22 and 26 also produce IL-2, specifically in response to CD33 positive target cells, indicating that the zeta-chain signalling capacity is intact in the fusion proteins. In fact cells expressing the fusion receptors at comparable levels on the cell surface produce on average more IL-2 in response to HL60 cells than HGT16 cell lines (from 50% more to 7-fold more), consistent with their capacity to provide both primary and co-stimulatory signals.

The function of the CD28 signalling domain can be confirmed by assaying for recruitment of downstream signalling components to the CD28 intracellular domain in response to receptor ligand binding. The association of the regulatory (p85) sub-unit of PI3-kinase with phosphorylated ITAM motifs of the sequence YMXM (single-letter amino acid code) in the CD28 intracellular domain in response to CD28 stimulation is well documented (eg Stein et al., 1994 Mol. Cell. Biol. 14: 3392-3402). CD28 also associates specifically with the tyrosine kinase ITK

on activation (August et al. 1994 Proc. Natl. Acad. Sci. USA 91: 9347-9351).

Association of p85 with the receptor chimeras is analysed by immunoprecipitation of the receptor and detection of bound p85 protein by Western blotting as follows. Approximately 5 x 10^7 cells are washed once with PBS and activated in 0.5 ml PBS containing 10 µg/ml rabbit anti-P67.6 idiotype antibody at 37°C for various times from 0 - 10 mins. Cells are then washed twice with ice-cold PBS and lysed in 1 ml lysis buffer as described above. Lysates are centrifuged at 15000 rpm in an Eppendorf micro-centrifuge for 10 min. and the supernatants immunoprecipitated with 100 µl protein A - sepharose beads (Pharmacia) at room tempeature for 30 min. (This immunoprecipitation procedure also serves to immunoprecipitate chimeric receptors containing antibody constant regions from cells which have not been stimulated with anti-idiotype antibody to act as a negative control). The beads are then washed 3 times with fresh lysis buffer, resuspended in 50 µl SDS loading buffer and subjected to SDS-PAGE and Western blotting. Blots are probed with mouse anti-p85 monoclonal antibody and HRP-conjugated rabbit anti-mouse Ig according to standard techniques.

This showed that p85 can associate with fusion receptors but not with the zeta chain chimera in cell line HGT16.1 thus confirming that p85 associates specifically with CD28 and not zeta and that CD28 signalling is retained in fusion chimeras.

Association of ITK with CD28 intracellular components is detected using published methods (August et al. 1994 Proc. Natl. Acad. Sci. USA 91: 9347-9351).

EXAMPLE 4

Expression of two hP67.6 - chimeric receptors in the same cell .

In order to express both a zeta chimeric receptor and a CD28 co-stimulatory receptor chimera in the same cell, stably transfected Jurkat cell lines expressing CD28 receptor chimeras were infected with recombinant adenovirus encoding the hP67.6 / G1 / Zeta chimeric receptor.

The hP67.6/h.28/CD28 construct was sub-cloned into pEE6hCMV.gpt and transsfected into Jurkat E6.1 cells as described in Example 2. Cell line HGT14.1 is a Jurkat trensfectant expressing this construct. The hP67.6/G1/CD28 construct was cloned into pEE6hCMV.ne and Jurkat clones HGT23.11 and HGT23.16 expressing this construct were isolated as in Example 2. The levels of expression of the CD28 chimeras on the surface of the transfected cells, determined by FAC-analysis with FITC-CD33 as described in Example 3, is shown in Figure 18.

In order to transiently express a uniform amount of the zeta-chain chimera hP67.6/G1/ zeta in each of these CD28-chimera cell lines, a recombinant adenovirus vector expressing the zeta chimera was constructed as follows. The hP67.6/G1/zeta coding sequence from pHMF342 (Example 1 and Table 2) was excised as a Not1 - Kpn1 fragment and inserted into the adenovirus-5 transfer vector pAL119 (provided by G. Wilkinson. Department of Medicine, University of Wales, Cardiff; unpublished) between the Not1 and BamH1 sites, after insertion of a Kpn1 - BamH1 adaptor oligonucleotide, to form pAL119-342. In this plasmid, the chimeric receptor coding sequences are expressed under the control of the hCMV-MIE promoter-regulatory region and polyadenylation signal (Wilkinson and Akrigg 1992 Nucl. Acids Res.20: 2233-2239).

Suitable alternative adenovirus transfer vectors containing the hCMV-MIE promoter include pCA3 and pCA4 (Hitt et al. 1995 in Methods in Molecular Genetics, K.W. Adolph (ed) Academic Press, Orlando.) Alternative adenovirus transfer vectors can be used such as pAC (Gerard and Meidell 1995 In DNA Cloning: a practical approach (2nd edition) Volume 4 ed Glover and Hames. IRL Press) which does not contain a promoter. In this case, one of many other heterologous promoters, such as the RSV-LTR

promoter or T-cell specific promoters. may be introduced upstream of the chimeric receptor coding sequence prior to insertion into the transfer vector. Additional RNA processing signals are also desirable, such as a polyadenylation signal (eg from SV40 Virus) and an intron (e.g. from the hCMV-MIE gene) (Bebbington (1991), Methods 2, 136-145).

Approximately 5 µg pAl119-342 was co-transfected with 5µg pJM17 (Microbix Biosystems Inc., McGrory et al. 1988 Virology 163: 614-617) into the human embryonic kidney cell line, 293 (ATCC CRL 1573) by calcium phosphate-mediated transfection, according to standard procedures for construction of adenovirus recombinants (Lowenstein et al 1996 in Protocols for gene transfer in Neuroscience, P.R. Lowenstein and L.W. Enquist (eds) Wiley and Sons). This generated recombinant virus RAd160 containing the chimeric receptor cDNA under the control of hCMV - MIE gene regulatory regions. Large scale preparations of RAd160 were prepared (Lowenstein et al ibid.) with titres of greater than 10^{10} pfu/ml and stored at -70°C in small aliquots.

Recombinant adenoviruses containing coding sequences for CD28 chimeric receptors are prepared in the same way after insertion of the desired coding sequence into pAL119 or another adenovirus transfer vector.

RAd160 was added to Jurkat E6.1 cells or transfectants expressing CD28 receptor -chimeras at a multiplicity of infection (MOI) of up to 400 pfu/cell with 2 µg/ml DEAE - Dextran and incubated for 24h at a cell concentration of 10^6 cells/ml in the presence of virus. Samples of ~~cells~~ were infected with a recombinant adenovirus expressing an irrelevant β-galactosidase protein RAd35 (Wilkinson and Akrigg 1992 Nucl. Acids Res.20: 2233-2239) in the same way to act as a negative control. Infected cells were then washed once in fresh growth medium, expanded in culture for a further 6 days and assayed for IL-2 production in response to target cells. The results are shown in Figure 19. Jurkat cells infected with RAd160 produce essentially undetectable levels of IL-2 in response to HL60-cell stimulation (less than 10 pg/ml) unless co-stimulated with 10 µg/ml anti-CD28 antibody 15E8 (Caltag) which leads to low levels of IL-2 production

specifically in response to HL60 cells and not in response to a cell ine which does not express human CD33, the murine SP2/0 cell line. In contrast, RAd160-infected HGT14.1 cells, which express a CD28 chimeric receptor, produce significant levels of IL-2 specifically in response to HL60 target cells even in the absence of anti-CD28 antibody. This indicates that the CD28-chimeric receptor hP67.6/h.28/CD28 is able to contribute the requisite co-stimulation to the zeta chimera. Cell lines expressing the alternative CD28 chimeric receptor, hP67.6/G1/CD28, 23.11 and 23.16 show markedly reduced levels of IL-2 production compared with 14.1. Indeed, 23.16, the cell line expressing the highest level of this CD28 chimera produces no detectable IL-2 at all. The CD28 signalling pathway was shown to be intact in this cell line since stimulation through CD3 (using anti-CD3 antibody) in 23.16 yields very high levels of IL-2 (results not shown). Thus the signalling defect in cell lines expressing the hP67/G1/CD28 chimera appears to be due to interference with zeta-chain signalling. The mechanism responsible is likely to be related to the use of the same extracellular domain in the zeta and CD28 chimeric receptors. This will allow heterodimerisation of the two receptors and this appears to interfere with zeta-chain signalling. This hypothesis is supported by the fact that 23.16, expressing high levels of the CD28 chimera, shows greater interference with zeta-chain signalling than 23.11, expressing very low levels of the CD28 chimera (Figure 18).

This experiment shows that it is possible to use the same scFv region to stimulate two chimeric receptor molecules in the same cell, one to provide a primary stimulus in response to antigen and the other receptor to provide a co-stimulatory signal. This leads to efficient IL-2 production specifically in response to antigen - expressing target cells provided that the two receptors are prevented from heterodimerisation, for instance by using different dimerisation domains on the two receptors. It is envisaged that additional pairs of dimerisation domains will be compatible. For instance the scFv/h.28/zeta chimeric receptor (Example 1; Figure 17) could provide the primary signal and the scFv/G1/CD28 receptor (Example 1: Figure 16) would provide the co-stimulatory signal.

EXAMPLE 5

Identification of additional co-stimulatory cell-surface receptors using anti-receptor antibodies.

5 x 10^5 HGT16.1 cells expressing the hP67.6 scFv/G1/zeta chimeric receptor (Example 3) were incubated for 16h with an equal number of HL60 cells in the presence of various mouse monoclonal antibodies directed against human T-cell surface markers. The bivalent antibodies were included at 10 µg/ml to test for their ability to co-stimulate the zeta - chain chimera. The antibodies used in this experiment were: anti-CD2 RPA2.10 (Pharmingen), anti-CD3 OKT3 (ATCC), anti-CD4 OKT4 (ATCC), anti-CD5 UCHT2 (Pharmingen), anti-CD28 15E8 (Caltag) and a control antibody MOPC21 (ATCC). IL-2 accumulated in the supernatant at the end of the incubation was measured by Quantikine IL-2 ELISA (R&D Systems).

The results indicate that anti-CD2, anti-CD5 and anti-CD28 co-stimulate production of IL-2 in HGT16.1 cells in response to HL60 target cells hence confirming CD2, CD5 and CD28 as co-stimulatory receptors compatible with zeta-chain chimera signalling. From experiments designed in this way, it would be possible to determine the co-stimulatory activity of other cell surface molecules. The intracellular domains can then be included in chimeric receptors as described in Example 1 and evaluated as described in Examples 2, 3 and 4.

EXAMPLE 6

Introduction of chimeric receptors into primary human CTLs.

In order to establish an assay for co-stimulation of cytolytic T-cell function, a zeta-chain chimera was introduced into primary human T-cells using recombinant adenovirus vectors. Peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteers using centrifugation over Ficoll-Hypaque (Pharmacia) according to the manufacturer's instructions and cultured in RPMI-1640 medium with 10% FCS in 175-cm^2 tissue culture flasks. Non-adherent cells were transferred to fresh tissue culture flasks after 24h and phytohaemagglutinin (PHA) was added to a final concentration of 2 µg/ml and human recombinant IL-2 at 50ng/ml. After 6 days, CD4 - positive cells were removed using anti-CD4 antibody

immobilised on magnetic Dynabeads (Becton - Dickinson) to leave a population of cells at least 95% CD8 - single positive (CTL cells). The cells were washed by centrifugation and resuspended in fresh medium +10% FCS at 10^6 cells /ml.

Recombinant adenovirus RAd160 (expressing the hP67.6/G1/zeta chimeric receptor, Example 4) or the control virus RAd35 was added to the cells at a multiplicity of infection (MOI) of up to 400 pfu/cell with 2 µg/ml DEAE-Dextran and incubated for 24h. Samples of cells were then fixed in 1% glutaraldehyde in PBS and infection rates measured by staining RAd35 - infected cells for β-galactosidase activity using 5-Bromo-4-chloro-3-indolyl β-D-galactoside (X-gal; Promega, according to the manufacturer's instructions). By this method, infection frequencies were determined to be at least 80%. Infected cells were expanded in culture for a further 6 days in medium containing 50 ng/ml human IL-2. In some experiments, 2mM sodium butyrate was added to infected CTL cells to induce expression from the hCMV-MIE promoter.

Cytolytic activity against the CD33-expressing tumour cell line HL60 was detected in recombinant adenovirus - infected CD8-positive cells incubated for 6 days in IL-2 and 2mM butyrate using standard 6h ^{51}Cr release assays. 2 x10^7 HL60 target cells were labelled by incubation with 25MBq ^{51}Cr (CJS4 Amersham) for 45 min. at 37oC in T-cell growth medium. After washing, 1.5 x 10^4 labelled HL60 cells were transferred into each well of a 96-well microtitre plate in the presence of RAd - infected CD8-positive effector cells at ratios in the range 100 to 0.1 effector:target cells. Cells were incubated for 6h in T-cell growth medium before centrifuging the plates and removal of the supernatant for counting. Cytolysis was expressed as the amount of ^{51}Cr released into the medium compared to that released by detergent treatment of target cells. In the experiment illustrated (Figure 20) specific lysis was mediated by RAd 160 - infected effector cells but not by CD8-positive cells infected with RAd35. The degree of specific lysis is increased with increased E:T ratio.

This assay is useful for determining the effects of co-stimulation on cytolytic function using anti-receptor antibodies, co-stimulatory cytokines

or co-stimulatory chimeric receptors. Cells starved of IL-2 for various lengths of time can also be used to increase the sensitivity of assays designed to evaluate co-stimulatory activities. CD28 chimeric receptors can be introduced by co-infection of recombinant adenovirus with RAd160. Alternatively a fusion receptor containing both zeta and CD28 signalling domains can be introduced using a single recombinant adenovirus. Anti-receptor antibodies which may be screened in this assay include anti-CD2 and anti-CD5 (see Example 5).

EXAMPLE 7

Analysis of co-stimulatory activities in Macrophages and Monocytes.

Human monocytes were isolated from peripheral blood as follows. PBMC were isolated as described above and adherent cells obtained by settling on to plastic tissue culture flasks for 24 h before washing extensively with fresh medium.

Primary macrophages were isolated from the peritoneal cavity of Wistar rats 5 days after i.p. injection of 5 ml 3% thioglycollate (Sigma T-9032) in saline according to the method of Argys (Argys 1967, J.Immunol. 99:744-750) or 3 ml mineral oil (heavy white oil; Sigma 400-5). Peritoneal lavage was carried out with 20ml RPMI 1640 medium + 10% FCS and 3.15% sodium citrate. Greater than 60% of the cells in the peritoneal lavage were mononuclear phagocytes as defined by flow cytometry using FITC-conjugated mouse anti-rat macrophage antibody ED2 (Serotec) and morphological characteristics. Adherent cells were enriched by applying cells to plastic flasks or 6-well plates in RPMI 1640 medium + 10% FCS and culturing for 2 days. Non-adherent cells were then removed by extensive washing with fresh medium. Alternatively, macrophages were purified by Percoll density centrifugation (Lawson and Stevenson 1983 Br. J. Cancer 48: 227-237.)

Monocytes and macrophages were maintained in culture for 48h and infected with recombinant adenoviruses at a MOI of up to 200 pfu/cell for 16h in the presence of 2 µg/ml DEAE-Dextran, after which the virus was removed by washing with fresh medium. Up to 80% of human peripheral - blood monocytes and rat peritoneal macrophages were infectable using

this procedure, as determined using X-gal staining of cells infected with RAd35. The use of higher concentrations of virus increased the percentage of cells infected but led to a significant reduction in cell viability.

The recombinant adenovirus RAd160 can be used to provide a human CD33-specific primary stimulus to cells of the rat or mouse monocyte - macrophage lineage. Since human monocytes express the CD33 antigen, for the analysis of chimeric receptor function in human monocytic phagocytes, it may be more appropriate to use an alternative binding specificity such as the hCTMO1scFv - containing chimeric receptor, constructed as in Example 1 and inserted into a recombinant adenovirus vector. Additionally, the zeta chain sequences of the chimeric receptor may be substituted with the transmembrane and intracelluar domain of a FcRIII γ chain (Park et al 1993, J. Clin. Invest. 92: 2073-2079).

Rat peritoneal macrophages infected with RAd160 at an MOI of 100 pfu/cell, expressed high levels of chimeric receptor on their surfaces 48h post-infection as determined by staining with FITC-CD33 and analysis by a FACScan flow cytometer.

The response of monocytes and macrophages expressing the appropriate chimeric receptor to stimulation with specific antigen or antigen-expressing cells recognised by the scFv is measured in standard ^{51}Cr release assays (Example 6). Alternatively, phagocytosis and cytostasis assays (Lawson and Stevenson 1983 Br. J. Cancer 48: 227-237) or assays for the release of cytokines are carried out eg human TNF ELISA (R&D Systems) or rat TNF ELISA (Biosource).

Identification of appropriate receptor intracellular domains to provide a co-stimulatory signal can be accomplished by incubation of macrophages expressing the chimeric receptor with a source of the specific antigen and with cross-linking antibodies or natural ligands specific for individual cell surface receptors present on monocytes and macrophages as described in Example 5. Suitable receptors include the IL-2 receptor, the CSF-1 receptor, the IFN-γ receptor, the GM-CSF receptor and TNF receptors.

Natural ligands which can be used for human monocytes / macrophages include recombinant human IL-2, human CSF-1 (M-CSF), human IFNγ, human GM-CSF and human TNFα (all from Genzyme). Ligands which can be used for rat or mouse macrophages include recombinant rat or human IL-2, human CSF-1 (M-CSF), mouse IFNγ, mouse GM-CSF and mouse TNFα (Genzyme). Species-specific antibodies which cross-link and stimulate the chosen receptors can be raised using standard techniques or can be identified by screening commercially available antibodies.

Those antibodies or natural ligands which co-stimulate macrophage responses to CD33 identify candidate receptors whose intracellular domains or associated signalling molecules, such as receptor - associated tyrosine kinases, can be used to produce chimeric co-stimulatory receptors or fusion receptors containing both co-stimulatory and primary signalling domains as described in Example 1. The intracellular components which may be used in these chimeric recptors include the following. The intracellular domains of the GM-CSF receptor β chain can be used as part of a di-sulphide linked homodimeric receptor or in combination with an intracelluar component from the α chain (Muto et al. 1996, J. Exp. Med. 183: 1911-1916). The intracelluar domains of the IFNγ-receptor α and β chains can be used (Bach et al., 1996.. Mol. Cell. Biol. 16: 3214-3221.), as can the intracellular domains of the IL-2 receptor, particularly the β and γ chains . One or more intracelluar tyrosine kinase components can be used such as the jak1, jak2 and jak3 kinases or the intracellular domain of the CSF-1 receptor tyrosine kinase (Carlberg and Rohrschneider 1994 Mol. Biol. Cell 5:81-95). If these tyrosine kinases are used, the receptors containing them are preferably constructed so that they are presented on the cell surface as monomers which oligomerise on binding of the scFv component to the target antigen, for instance using a scFv coupled to a CD8 hinge extracellular component , coupled to a CD28 transmembrane component (see Example 1) which is coupled to the tyrosine kinase component.

EXAMPLE 8

Analysis of co-stimulatory activities in other cells of the immune system

Additional immune cell types such as CD4-positive T-cells, B-cells, NK cells, basophils, neutrophils, haematopietic stem cells are isolated from human peripheral blood, mouse or rat blood or peritoneal cavity or other sources by published procedures (Current Protocols in Immunology ed Coligan et al. John Wiley and Sons). Established cell lines which retain the differentiated functions of various immne cell types can also be used eg the human NK-like cell line YT2C2 (Roger et al 1996 Cellular Immunol. 168: 24-32.) A chimeric receptor capable of delivering a primary stimulus such as the hP67.6/G1/zeta chimera described above is introduced into the isolated immune cell type, eg by infection with recombinant adenovirus RAd160, and cross-linking antibodies or natural ligands of cell surface receptors are used to identify cell-surface molecules capable of providing co-stimulatory signals as described in Example 7.

Chimeric receptors containing appropriate cytoplasmic components to provide suitable co-stimulatory functions are then constructed as described in Example 1. The function of the chimeric receptors in the chosen cell types can be analysed using recombinant adenovirus vectors.

POSSIBLE CHIMERIC RECEPTOR COMBINATIONS

TABLE 1

	LIGAND BINDING	SPACER	TRANS MEMBRANE	SPACER	CYTOSOLIC COMPONENT	SPACER	CYTOSOLIC COMPONENT	SPACER	CYTOSOL SPACERS*
A	TAA SCFV	G1	TCR ZETA	OPT**	TCR ZETA	OPT	OPT	OPT	OPT
	TAA SCFV	h	CD28	OPT	CD28	OPT	OPT	OPT	OPT
B	TAA SCFV	CD8	TCR ZETA	OPT	TCR ZETA	OPT	OPT	OPT	OPT
	TAA SCFV	h	CD28	OPT	CD28	OPT	OPT	OPT	OPT
C	TAA SCFV	G1	TCR ZETA	OPT	TCR ZETA	OPT	OPT	OPT	OPT
	TAA SCFV	G1	IL2 R β	OPT	IL2 R β	OPT	IL2 R γ	OPT	OPT
D	TAA SCFV	G1	TCR ZETA	OPT	TCR ZETA	OPT	CD28	OPT	OPT
E	TAA SCFV	h	TCR ZETA	OPT	TCR ZETA	OPT	CD28	OPT	OPT
F	TAA SCFV	G1	TCR ZETA	OPT	TCR ZETA	OPT	IL2 R β	OPT	IL2 R γ

A,B and C describe pairs of genes coding for pairs of chimeric receptors
D,E and F describe fusion chimeric receptors, as shown in C one of a pair of receptors may be a fusion receptor

TAA SCFV denotes a single chain FV to a Tumour associated antigen
For a pair of chimeric receptors the SCFVs may bind the same or different epitopes of the same antigen or different antigens on the same or different cells.

G1 is the IgG CH 3 CH 2 HINGE spacer construct described in the text
h denotes theIgG hinge plus part of the CD28 extracellular component described in the text

* one or more further cytosolic and or spacer components

** OPT = optional

TABLE 2

CHIMERIC RECEPTOR CONSTRUCTS AND CELL LINE NOMENCLATURE

CONSTRUCT	CONSTRUCTION PLASMID	EXPRESSION PLASMID	CELL LINES
hCTMO1 scFv / CD8 / TCR zeta	pBS3	pTB3	TB3
hP67.6 scFv / CD8 / TCR zeta	pBS5	pTB5	TB5
hCTMO1 scFv / CD8 / CD28	pHMF 320	pHMF 332	HGT 1
hCTMO1 scFv / CD8 / TCR zeta-CD28	pHMF 326	pHMF 334	HGT 2
hP67.6 scFv / G1 / TCR zeta	pHMF 342	pHMF 351	HGT 6 & 16
hP67.6 scFv / G1 / TCR zeta-CD28	pHMF 354	pHMF 355	HGT 7 & 17
hP67.6 scFv / h / CD28	pHMF 350	pHMF 353	HGT 8 & 14
hP67.6 scFv / G1 / CD28	pHMF 375	pHMF 376	HGT 23
hP67.6 scFv / G1 / CD28-TCR zeta	pHMF 372	pHMF 373	HGT 21
hP67.6 scFv / G1 / CD28-TCR zeta-CD28	pHMF 379	pHMF 380	HGT 26
hP67.6 scFv / h.28 / TCR zeta	pHMF 377	pHMF 378	HGT 24
hP67.6 scFv / h.28 / TCR zeta - CD28	pHMF 363	pHMF 364	HGT 20
hP67.6 scFv / h.28 / CD28 - TCR zeta	pHMF 369	pHMF 371	HGT 22

G1 is the IgG hinge CH2 CH3 spacer

h is the IgG hinge component plus part of CD28 extracellular domain spacer.

h.28 is the IgG hinge component plus part of CD28 extracellular domain and amino acid residues L, D, P & K spacer.

Expression plasmids pTB3 and pTB5, pHMF 334, 351, 355, 378 and 364 include the TCR zeta transmembrane domain.

Expression plasmids pHMF 332, 353, 376, 373, 380 and 371 include the CD28 transmembrane domain.

CLAIMS

1. A method of activating a cell as a result of one type of extracellular interaction between said first cell and a molecule associated with a second target cell characterised in that said first cell is provided with a DNA delivery system comprising DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling components, wherein said cytoplasmic components are not naturally linked, and at least one is derived from a membrane spanning polypeptide.

2. A method according to Claim 1 wherein the cytoplasmic signalling components are capable of acting together cooperatively.

3. A method according to Claim 1 or Claim 2 wherein said DNA additionally codes for signal peptide, binding and/or transmembrane components of said one or more chimeric receptors, wherein the binding component is capable of recognising a cell surface molecule on a target cell.

4. A method according to Claim 3 wherein the signal peptide, transmembrane and cytoplasmic signalling components and all or part of the binding component are coded for by a single DNA coding sequence.

5. A method according to Claim 3 wherein each cytoplasmic signalling component is coded for by a separate DNA coding sequence, each of DNA sequence additionally coding for a signal peptide, a transmembrane component and all or part of a binding component.

6. A method according to Claim 4 or Claim 5 wherein said DNA codes for part of said binding component and an additional separate DNA coding sequence codes for the remainder of the binding component.

7. A method according to Claim 5 or Claim 6 wherein the binding component coded for by one DNA sequence is capable of

participating in the same type of extracellular binding event as the binding component coded for by any other DNA sequence.

8. A method according to Claim 7 wherein each binding component binds to the same molecule associated with the target cell.

9. A method according to Claim 8 wherein each binding component is the same.

10. A method according to any one of Claims 1 to 9 wherein the one or more recombinant chimeric receptors are capable of recognising a viral or cell surface molecule on a target cell.

11. A DNA delivery system comprising DNA in association with a carrier said DNA coding for a recombinant chimeric receptor capable of one type of extracellular interaction and comprising two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide.

12. A DNA delivery system comprising DNA in association with a carrier said DNA coding for two or more recombinant chimeric receptors each capable of the same one type of extracellular interaction and wherein each of said receptors comprises one or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide.

13. A DNA delivery system according to Claim 11 wherein said DNA codes in reading frame for:

i) a signal peptide component;

ii) a binding component capable of recognising a cell surface molecule on a target cell;

iii) a transmembrane component;

iv) two or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic

components is derived from a membrane spanning polypeptide: and optionally

v) one or more spacer regions linking any two or more of said i) to iv) components.

14. A DNA delivery system according to Claim 11 wherein said DNA comprises 1) a first DNA which codes in reading frame for:

i) a signal peptide component;

ii) part of a binding component;

iii) a transmembrane component;

iv) two or more cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide: and optionally

v) one or more spacer regions linking any two or more of said i) to iv) components; and 2) a second separate DNA which codes in reading frame for a signal peptide component and a further part of the binding component ii) coded for by said first DNA, such that the binding component parts together are capable of recognising a cell surface molecule on a target cell.

15. A DNA delivery system according to Claim 12 wherein said DNA comprises a first and a second separate DNA each of which codes in reading frame for:

i) a signal peptide component;

ii) a binding component capable of recognising a cell surface molecule on a target cell;

iii) a transmembrane component;

iv) one or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide: and optionally

v) one or more spacer regions linking any two or more of said i) to iv) components; provided that said first DNA codes for at least one signalling component iv) that is not coded for by said second DNA.

16. A DNA delivery system according to Claim 12 wherein said DNA comprises 1) a first and a second separate DNA each of which codes in reading frame for:

i) a signal peptide component;

ii) one part of a binding component;

iii) a transmembrane component;

iv) one or more different cytoplasmic signalling components which are not naturally linked, and wherein at least one of said cytoplasmic components is derived from a membrane spanning polypeptide; and optionally

v) one or more spacer regions linking any two or more of said i) to iv) components; provided that said first DNA codes for at least one signalling component iv) that is not coded for by said second DNA; and 2) a separate third and fourth DNA each of which codes in reading frame for a signal peptide component and a further part of the binding component ii) coded for by said first and second DNA respectively, such that the binding component parts together provided by the first and third DNA and together provided by t he second and fourth DNA are each capable of recognising a cell surface molecule on a target cell.

17. A DNA delivery system according to Claims 13 to 16 wherein each signal peptide component is an immunoglobulin signal sequence.

18. A DNA delivery system according to Claims 15 to 17 wherein the binding component coded for by said first DNA is the same as the binding component coded for by said second DNA.

19. A DNA delivery system according to Claims 13 to 18 wherein the binding component is an antibody or an antigen binding fragment thereof.

20. A DNA delivery system according to Claim 19 wherein the antibody or fragment thereof is an engineered human antibody or antigen binding fragment thereof.

21. A DNA delivery system according to Claims 18 to 20 wherein the binding component is a single chain Fv fragment.

22. A DNA delivery system according to Claims 18 to 20 wherein the binding component is a Fab' fragment.

23. A DNA delivery system according to any one of Claims 13 to 22 wherein the transmembrane component is derived from all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, a cytokine receptor or a colony stimulating factor receptor.

24. A DNA delivery system according to Claim 23 wherein the transmembrane component is derived from all or part of CD28.

25. A DNA delivery system according to any one of Claims 11 to 24 wherein the cytoplasmic signalling components are capable of acting together cooperatively.

26. A DNA delivery system according to any one of Claims 13 to 25 wherein the cytoplasmic signalling components are derived from all or part of the cytoplasmic domains of a zeta, eta or epsilon chain of the T-cell receptor. CD28, the γ chain of a Fc receptor, a cytokine receptor, a colony stimulating factor receptor, a tyrosine kinase or an adhesion molecule, B29, MB-1, CD3 delta, CD3 gamma, CD5 or CD2.

27. A DNA delivery system according to Claim 26 wherein the cytoplasmic signalling components are ITAM containing cytoplasmic components.

28. A DNA delivery system according to Claim 26 or Claim 27 wherein the cytoplasmic signalling components are derived from all or part of CD28 and/or the zeta chain of the T-cell receptor.

29. A DNA delivery system according to any one of Claims 11 to 28 wherein the cytoplasmic signalling components are in any orientation relative to one another.

30. A DNA delivery system according to any one of Claims 13 to 29 wherein said DNA coding for components i) to iv) additionally codes for one or more spacer regions linking the binding component ii) and the transmembrane component iii).

31. A DNA delivery system according to Claim 30 wherein two or more different spacer regions link the binding component ii) and the transmembrane component iii), both regions either being coded for by one DNA sequence or when a first and second DNA sequence is present one region being coded for by said first DNA and the other different region being coded for by said second DNA.

32. A DNA delivery system according to Claims 30 or Claim 31 wherein the spacer region is selected to provide one or more free thiol groups.

33. A DNA delivery system according to Claims 30 to 32 wherein the spacer region is derived from all or part of the extracellular region of CD8, CD4 or CD28 .

34. A DNA delivery system according to Claims 30 or Claim 32 wherein the spacer region is all or part of an antibody constant region.

35. A DNA delivery system according to Claims 30 to 32 wherein the spacer region is derived from all or part of an antibody hinge region linked to all or part of the extracellular region of CD28.

36. A DNA delivery system according to any one of Claims 11 to 35 wherein the carrier is a viral vector or a non-viral vector.

37. A DNA delivery system according to Claim 36 wherein the non-viral vector is a liposomal vector.

38. A DNA delivery system according to Claim 37 wherein the carrier is a targeted non-viral vector.

39. A DNA delivery system according to Claim 38 wherein the targeted vector is an antibody targeted liposome.

40. A DNA delivery system according to Claim 38 wherein the targeted vector is an antibody targeted condensed DNA.

41. A DNA delivery system according to Claim 40 wherein the targeted vector is an antibody targeted protamine or polylysine condensed DNA.

42. A DNA delivery system according to Claim 38 wherein the targeted vector is antibody targeted naked DNA.

43. A DNA delivery system according to Claims 39 to 42 wherein the antibody is a whole antibody or an antigen binding fragment thereof.

44. A DNA delivery system according to Claim 43 wherein the antibody is an engineered human antibody or an antigen binding fragment thereof.

45. An effector cell transfected with a DNA delivery system according to any one of Claims 1 to 444.

46. An effector cell according to Claim 45 which is a lymphocyte, a dendritic cell, a B-cell, a haematopoietic stem cell, a macrophage, a monocyte or a NK cell.

47. An effector cell according to Claim 46 which is a cytotoxic T-lymphocyte.

48. A DNA delivery system according to any one of Claims 11 to 47 for use in the treatment of infectious disease, inflammatory disease.

cancer, allergic/atopic disease, congenital disease, dermatologic disease, neurologic disease, transplants and metabolic/idiopathic disease.

49. A DNA delivery system according to Claim 48 for use in the treatment of rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, asthma, eczema, cystic fibrosis, sickle cell anaemia, psoriasis, multiple sclerosis, organ or tissue transplant rejection, graft-versus-host disease or diabetes.

50. A pharmaceutical composition comprising a DNA delivery system according to any one of Claims 11 to 44 together with one or more formulatory agents.

51. A pharmaceutical composition according to Claim 50 wherein the formulatory agent is a suspending, preservative, stabilising and/or dispersing agent.

52. DNA coding for a recombinant chimeric receptor for use in a delivery system according to any one of Claims 11 to 44.

FIG. 1
Construct cassettes cloned into pBluescript SK +

scFv / CD8 /Zeta Chimeric Receptor



scFv / CD8 / Zeta-CD28 fusion Chimeric Receptor



scFv / CD8 / CD28 Chimeric Receptor



FIG. 2a

Construct cassettes cloned into pBluescript SK +

scFv / G1 /Zeta Chimeric Receptor



scFv / G1 / Zeta-CD28 fusion Chimeric Receptor



scFv / h / CD28 Chimeric Receptor



FIG. 2b

Construct cassettes cloned into pBluescript SK +

scFv /G1 /CD28 Chimeric Receptor



scFv /G1 /CD28-Zeta fusion Chimeric Receptor



scFv /G1 /CD28-Zeta-CD28 fusion Chimeric Receptor



FIG. 2c
Construct cassettes cloned into pBluescript SK +

scFv /h.28 /Zeta Chimeric Receptor



scFv / h.28 /Zeta - CD28 fusion Chimeric Receptor



scFv /h.28 /CD28-Zeta fusion Chimeric Receptor



FIG. 3

OLIGONUCLEOTIDE SEQUENCES FOR T-BODY CONSTRUCTION

All oligos listed in the 5' to 3' orientation.

R6490 : ATA TAG CGG CCG CAA GCT TCC ACC ATG TCT GTC CCC ACC CAA GTC CTC

R6491 : TGA CCC TCC GCC ACC TGA CCC TCC GCC ACC TGA CCC TCC GCC ACC TGA CCC TCC GCC ACC TGA CCC TCC GCC ACC TTT TAC TTC TAC TTT AGT ACC

R6492 : GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GAG GTG CAG CTG GTG CAG TCT

R6493 : TAT ATA CTA GTA GAA GAC ACT GTC ACC AGT

R6516 : TGA CCC TCC GCC ACC TGA CCC TCC GCC ACC TGA CCC TCC GCC ACC TGA CCC TCC GCC ACC CGT ACG TTT TAC TTC TAC TTT

R6515 : GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA CAG ATT CAG CTG GTG CAG TCT

R6514 : TAT ATA CTA GTC GGG CCC TTC GTT GAG GCA

R6494 : ATA TAA CTA GTA ACT CCA TCA TGT ACT TCA GCC ACT TCG TGC CGG TCT TCC TGC CAG CG

R6495 : CGG TGT TGG TGG TCG CGG CGC TGG CGT CGT GGT GGG CTT CGC TGG CAG GAA GAC CGG CAC

R6496 : GCG CCG CGA CCA CCA ACA CCG GCG CCC ACC ATC GCG TCG CAG CCC CTG TCC CTG CGC CCA

R6497 : TAT ATG GAT CCA GCA GGC CAA AGC TCT GCG CCT CTG GGC GCA GGG ACA GGG GCT G

R6506 : TAT ATG GAT CCC GCC TCT GGG CGC AGG GAC AGG GGC TG

R6488 : ATA TAG GAT CCC AAA CTC TGC TAC CTG CTG

FIG. 3 (contd.)

R6489 : TAT ATG AAT TCT TAG CGA GGG GGC AGG GCC TGC AT

P3240 : TAT GGA TCC AAG CCC TTT TGG GTG CTG GTG GTG

P3241 : TAT GAA TTC TCA GGA GCG ATA GGC TGC GAA

P3301 : GCC ACC AAG GAC ACC TAC GAC GC

P3302 : CCC CCT CGC AGG AGT AAG AGG AGC AGG CTC CTG CAC AGT GAC TAC ATG AAC ATG ACT CCC C

P3303 : CAA GCA TTA CCA GCC CTA TGC CCC ACC ACG CGA CTT CGC AGC CTA TCG CTC CTG AGA ATT CAT A

P3304 : TAT GAA TTC TCA GGA GCG ATA G

P3305 : GCA TAG GGCTGG TAA TGC TTG CGG GTG GGC CCG GGG CGG CGG GGA GTC ATG TTC ATG TAG T

P3306 : CTC TTA CTC CTG CGA GGG GGC AGG GCC TGC ATG TGA AGG GCG TCG TAG GTG TCC TTG GTG GC

S0146 : CGA CTA GTG ACA AAA CTC ACA CAT GCC CAC CGT GCC CAA AAG GGA AAC ACC TTT GTC CAA GGT CCC

S0060 . CGA CTA GTG ACA AAA CTC ACA CAT GCC CAC CG

S0061 : TTG GGA TCC AGT TTA CCC GGA GAC AGG GAG AGG CT

T4057: CTA CTA GTG ACA AAA CTC ACA C

T4058: TTG GGA TCC AGG GGC TTA GAA GGT CCG GGA AAT AG

T7145: CTG GAT CCC AAA TTT TGG GTG CTG GTG GTG GTT G

T4060: GCT CCT GCT GAA CTT CAC TCT GGA GCG ATA GGC TGC GAA GTC G

T4387: GCG ACT TCG CAG CCT ATC GCT CCA GAG TGA AGT TCA GCA GGA GCG

S4700: TAT GAA TTC TTA GCG AGG GGG CAG GGC CTG CAT G

FIG.4

SEQUENCE OF hCTMO1 / CD8 /ZETA RECOMBINANT CHIMERIC RECEPTOR

```
          10          20          30          40
          *           *           *           *
ATG TCT GTC CCC ACC CAA GTC CTC GGA CTC CTG CTG CTG TGG
TAC AGA CAG GGG TGG GTT CAG GAG CCT GAG GAC GAC GAC ACC
 M   S   V   P   T   Q   V   L   G   L   L   L   L   W>

        50          60          70          80
        *           *           *           *
CTT ACA GAT GCC AGA TGC GAT ATC CAG ATG ACT CAG AGT CCA
GAA TGT CTA CGG TCT ACG CTA TAG GTC TAC TGA GTC TCA GGT
 L   T   D   A   R   C   D   I   Q   M   T   Q   S   P>

     90          100         110         120
     *           *           *           *
AGT ACT CTC AGT GCC AGT GTA GGT GAT AGG GTC ACC ATC ACT
TCA TGA GAG TCA CGG TCA CAT CCA CTA TCC CAG TGG TAG TGA
 S   T   L   S   A   S   V   G   D   R   V   T   I   T>

   130         140         150         160
   *           *           *           *
TGT AGG AGT AGT AAA AGT CTC CTC CAT AGT AAC GGT GAC ACC
ACA TCC TCA TCA TTT TCA GAG GAG GTA TCA TTG CCA CTG TGG
 C   R   S   S   K   S   L   L   H   S   N   G   D   T>

170         180         190         200         210
*           *           *           *           *
TTC CTC TAT TGG TTC CAG CAG AAA CCA GGT AAA GCC CCA AAG
AAG GAG ATA ACC AAG GTC GTC TTT GGT CCA TTT CGG GGT TTC
 F   L   Y   W   F   Q   Q   K   P   G   K   A   P   K>

          220         230         240         250
          *           *           *           *
CTC CTC ATG TAT AGG ATG AGT AAC CTC GCC AGT GGT GTA CCA
GAG GAG TAC ATA TCC TAC TCA TTG GAG CGG TCA CCA CAT GGT
 L   L   M   Y   R   M   S   N   L   A   S   G   V   P>

        260         270         280         290
        *           *           *           *
TCT AGA TTC AGT GGT AGT GGT AGT GGT ACT GAG TTC ACT CTC
AGA TCT AAG TCA CCA TCA CCA TCA CCA TGA CTC AAG TGA GAG
 S   R   F   S   G   S   G   S   G   T   E   F   T   L>

     300         310         320         330
     *           *           *           *
ACT ATC AGT AGT CTC CAG CCA GAT GAT TTC GCC ACT TAT TAT
TGA TAG TCA TCA GAG GTC GGT CTA CTA AAG CGG TGA ATA ATA
 T   I   S   S   L   Q   P   D   D   F   A   T   Y   Y>

   340         350         360         370
   *           *           *           *
TGT ATG CAG CAT CTC GAA TAT CCA TTC ACT TTC GGT CAG GGT
ACA TAC GTC GTA GAG CTT ATA GGT AAG TGA AAG CCA GTC CCA
 C   M   Q   H   L   E   Y   P   F   T   F   G   Q   G>

380         390         400         410         420
*           *           *           *           *
ACT AAA GTA GAA GTA AAA CGT ACG GGT GGC GGA GGG TCA GGT
TGA TTT CAT CTT CAT TTT GCA TGC CCA CCG CCT CCC AGT CCA
 T   K   V   E   V   K   R   T   G   G   G   G   S   G>
```

FIG. 4(contd.)

```
          430         440         450         460
           *           *           *           *
GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA
CCG CCT CCC AGT CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT
 G   G   G   S   G   G   G   G   S   G   G   G   G   S>

      470         480         490         500
       *           *           *           *
GGT GGC GGA GGG TCA CAG ATT CAG CTG GTG CAG TCT GGA GCA
CCA CCG CCT CCC AGT GTC TAA GTC GAC CAC GTC AGA CCT CGT
 G   G   G   G   S   Q   I   Q   L   V   Q   S   G   A>

    510         520         530         540
     *           *           *           *
GAG GTG AAG AAG CCT GGA TCT TCT GTG AAG GTG TCT TGT AAG
CTC CAC TTC TTC GGA CCT AGA AGA CAC TTC CAC AGA ACA TTC
 E   V   K   K   P   G   S   S   V   K   V   S   C   K>

  550         560         570         580
   *           *           *           *
GCA TCT GGA TAC ACC TTC ACC GAC TAC TAC ATT AAT TGG ATG
CGT AGA CCT ATG TGG AAG TGG CTG ATG ATG TAA TTA ACC TAC
 A   S   G   Y   T   F   T   D   Y   Y   I   N   W   M>

590         600         610         620         630
 *           *           *           *           *
AGA CAG GCA CCT GGA CAG GGA CTC GAG TGG ATT GGA TGG ATT
TCT GTC CGT GGA CCT GTC CCT GAG CTC ACC TAA CCT ACC TAA
 R   Q   A   P   G   Q   G   L   E   W   I   G   W   I>

          640         650         660         670
           *           *           *           *
GAC CCT GGA TCT GGA AAT ACA AAG TAC AAT GAG AAG TTC AAG
CTG GGA CCT AGA CCT TTA TGT TTC ATG TTA CTC TTC AAG TTC
 D   P   G   S   G   N   T   K   Y   N   E   K   F   K>

      680         690         700         710
       *           *           *           *
GGA AGA GCA ACA CTG ACA GTG GAC ACA TCC ACG AAT ACC GCC
CCT TCT CGT TGT GAC TGT CAC CTG TGT AGG TGC TTA TGG CGG
 G   R   A   T   L   T   V   D   T   S   T   N   T   A>

    720         730         740         750
     *           *           *           *
TAC ATG GAG CTG TCT TCT CTG AGA TCT GAG GAC ACA GCA TTC
ATG TAC CTC GAC AGA AGA GAC TCT AGA CTC CTG TGT CGT AAG
 Y   M   E   L   S   S   L   R   S   E   D   T   A   F>

  760         770         780         790
   *           *           *           *
TAC TTC TGT GCA AGA GAG AAG ACC ACC TAC TAC TAC GCA ATG
ATG AAG ACA CGT TCT CTC TTC TGG TGG ATG ATG ATG CGT TAC
 Y   F   C   A   R   E   K   T   T   Y   Y   Y   A   M>

800         810         820         830         840
 *           *           *           *           *
GAC TAC TGG GGA CAG GGA ACA CTG GTG ACA GTG TCT TCT GCC
CTG ATG ACC CCT GTC CCT TGT GAC CAC TGT CAC AGA AGA CGG
 D   Y   W   G   Q   G   T   L   V   T   V   S   S   A>
```

FIG. 4(contd.)

```
          850         860         870         880
           *           *           *           *
TCA ACG AAG GGC CCG ACT AGT AAC TCC ATC ATG TAC TTC AGC
AGT TGC TTC CCG GGC TGA TCA TTG AGG TAG TAC ATG AAG TCG
 S   T   K   G   P   T   S   N   S   I   M   Y   F   S>

      890         900         910         920
       *           *           *           *
CAC TTC GTG CCG GTC TTC CTG CCA GCG AAG CCC ACC ACG ACG
GTG AAG CAC GGC CAG AAG GAC GGT CGC TTC GGG TGG TGC TGC
 H   F   V   P   V   F   L   P   A   K   P   T   T   T>

    930         940         950         960
     *           *           *           *
CCA GCG CCG CGA CCA CCA ACA CCG GCG CCC ACC ATC GCG TCG
GGT CGC GGC GCT GGT GGT TGT GGC CGC GGG TGG TAG CGC AGC
 P   A   P   R   P   P   T   P   A   P   T   I   A   S>

  970         980         990         1000
   *           *           *           *
CAG CCC CTG TCC CTG CGC CCA GAG GCG CAG AGC TTT GGC CTG
GTC GGG GAC AGG GAC GCG GGT CTC CGC GTC TCG AAA CCG GAC
 Q   P   L   S   L   R   P   E   A   Q   S   F   G   L>

1010        1020        1030        1040        1050
  *           *           *           *           *
CTG GAT CCC AAA CTC TGC TAC CTG CTG GAT GGA ATC CTC TTC
GAC CTA GGG TTT GAG ACG ATG GAC GAC CTA CCT TAG GAG AAG
 L   D   P   K   L   C   Y   L   L   D   G   I   L   F>

          1060        1070        1080        1090
           *           *           *           *
ATC TAT GGT GTC ATT CTC ACT GCC TTG TTC CTG AGA GTG AAG
TAG ATA CCA CAG TAA GAG TGA CGG AAC AAG GAC TCT CAC TTC
 I   Y   G   V   I   L   T   A   L   F   L   R   V   K>

      1100        1110        1120        1130
       *           *           *           *
TTC AGC AGG AGC GCA GAC GCC CCC GCG TAC CAG CAG GGC CAG
AAG TCG TCC TCG CGT CTG CGG GGG CGC ATG GTC GTC CCG GTC
 F   S   R   S   A   D   A   P   A   Y   Q   Q   G   Q>

    1140        1150        1160        1170
     *           *           *           *
AAC CAG CTC TAT AAC GAG CTC AAT CTA GGA CGA AGA GAG GAG
TTG GTC GAG ATA TTG CTC GAG TTA GAT CCT GCT TCT CTC CTC
 N   Q   L   Y   N   E   L   N   L   G   R   R   E   E>

  1180        1190        1200        1210
   *           *           *           *
TAC GAT GTT TTG GAC AAG AGA CGT GGC CGG GAC CCT GAG ATG
ATG CTA CAA AAC CTG TTC TCT GCA CCG GCC CTG GGA CTC TAC
 Y   D   V   L   D   K   R   R   G   R   D   P   E   M>

1220        1230        1240        1250        1260
  *           *           *           *           *
GGG GGA AAG CCG AGA AGG AAG AAC CCT CAG GAA GGC CTG TAC
CCC CCT TTC GGC TCT TCC TTC TTG GGA GTC CTT CCG GAC ATG
 G   G   K   P   R   R   K   N   P   Q   E   G   L   Y>
```

FIG. 4(contd)

```
          1270          1280          1290          1300
            *             *             *             *
AAT GAA CTG CAG AAA GAT AAG ATG GCG GAG GCC TAC AGT GAG
TTA CTT GAC GTC TTT CTA TTC TAC CGC CTC CGG ATG TCA CTC
 N   E   L   Q   K   D   K   M   A   E   A   Y   S   E>

      1310          1320          1330          1340
        *             *             *             *
ATT GGG ATG AAA GGC GAG CGC CGG AGG GGC AAG GGG CAC GAT
TAA CCC TAC TTT CCG CTC GCG GCC TCC CCG TTC CCC GTG CTA
 I   G   M   K   G   E   R   R   R   G   K   G   H   D>

    1350          1360          1370          1380
      *             *             *             *
GGC CTT TAC CAG GGT CTC AGT ACA GCC ACC AAG GAC ACC TAC
CCG GAA ATG GTC CCA GAG TCA TGT CGG TGG TTC CTG TGG ATG
 G   L   Y   Q   G   L   S   T   A   T   K   D   T   Y>

  1390          1400          1410          1420
    *             *             *             *
GAC GCC CTT CAC ATG CAG GCC CTG CCC CCT CGC TAA
CTG CGG GAA GTG TAC GTC CGG GAC GGG GGA GCG ATT
 D   A   L   H   M   Q   A   L   P   P   R   *
```

FIG.5

SEQUENCE OF hCTMO1 / CD8 /Zeta-CD28 FUSION RECOMBINANT CHIMERIC RECEPTOR

```
          10          20          30          40
           *           *           *           *
ATG TCT GTC CCC ACC CAA GTC CTC GGA CTC CTG CTG CTG TGG CTT ACA
TAC AGA CAG GGG TGG GTT CAG GAG CCT GAG GAC GAC GAC ACC GAA TGT
 m   s   v   p   t   q   v   l   g   l   l   l   l   w   l   t>

50          60          70          80          90
 *           *           *           *           *
GAT GCC AGA TGC GAT ATC CAG ATG ACT CAG AGT CCA AGT ACT CTC AGT
CTA CGG TCT ACG CTA TAG GTC TAC TGA GTC TCA GGT TCA TGA GAG TCA
 d   a   r   c   D   I   Q   M   T   Q   S   P   S   T   L   S>

  100         110         120         130         140
   *           *           *           *           *
GCC AGT GTA GGT GAT AGG GTC ACC ATC ACT TGT AGG AGT AGT AAA AGT
CGG TCA CAT CCA CTA TCC CAG TGG TAG TGA ACA TCC TCA TCA TTT TCA
 A   S   V   G   D   R   V   T   I   T   C   R   S   S   K   S>

    150         160         170         180         190
     *           *           *           *           *
CTC CTC CAT AGT AAC GGT GAC ACC TTC CTC TAT TGG TTC CAG CAG AAA
GAG GAG GTA TCA TTG CCA CTG TGG AAG GAG ATA ACC AAG GTC GTC TTT
 L   L   H   S   N   G   D   T   F   L   Y   W   F   Q   Q   K>

        200         210         220         230         240
         *           *           *           *           *
CCA GGT AAA GCC CCA AAG CTC CTC ATG TAT AGG ATG AGT AAC CTC GCC
GGT CCA TTT CGG GGT TTC GAG GAG TAC ATA TCC TAC TCA TTG GAG CGG
 P   G   K   A   P   K   L   L   M   Y   R   M   S   N   L   A>

          250         260         270         280
           *           *           *           *
AGT GGT GTA CCA TCT AGA TTC AGT GGT AGT GGT AGT GGT ACT GAG TTC
TCA CCA CAT GGT AGA TCT AAG TCA CCA TCA CCA TCA CCA TGA CTC AAG
 S   G   V   P   S   R   F   S   G   S   G   S   G   T   E   F>

290         300         310         320         330
 *           *           *           *           *
ACT CTC ACT ATC AGT AGT CTC CAG CCA GAT GAT TTC GCC ACT TAT TAT
TGA GAG TGA TAG TCA TCA GAG GTC GGT CTA CTA AAG CGG TGA ATA ATA
 T   L   T   I   S   S   L   Q   P   D   D   F   A   T   Y   Y>

  340         350         360         370         380
   *           *           *           *           *
TGT ATG CAG CAT CTC GAA TAT CCA TTC ACT TTC GGT CAG GGT ACT AAA
ACA TAC GTC GTA GAG CTT ATA GGT AAG TGA AAG CCA GTC CCA TGA TTT
 C   M   Q   H   L   E   Y   P   F   T   F   G   Q   G   T   K>

    390         400         410         420         430
     *           *           *           *           *
GTA GAA GTA AAA CGT ACG GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA
CAT CTT CAT TTT GCA TGC CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT
 V   E   V   K   R   T   G   G   G   G   S   G   G   G   G   S>
```

FIG. 5(contd.)

```
        440         450         460         470         480
         *           *           *           *           *
GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA CAG
CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT GTC
 G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   Q>

          490         500         510         520
           *           *           *           *
ATT CAG CTG GTG CAG TCT GGA GCA GAG GTG AAG AAG CCT GGA TCT TCT
TAA GTC GAC CAC GTC AGA CCT CGT CTC CAC TTC TTC GGA CCT AGA AGA
 I   Q   L   V   Q   S   G   A   E   V   K   K   P   G   S   S>

530         540         550         560         570
 *           *           *           *           *
GTG AAG GTG TCT TGT AAG GCA TCT GGA TAC ACC TTC ACC GAC TAC TAC
CAC TTC CAC AGA ACA TTC CGT AGA CCT ATG TGG AAG TGG CTG ATG ATG
 V   K   V   S   C   K   A   S   G   Y   T   F   T   D   Y   Y>

  580         590         600         610         620
   *           *           *           *           *
ATT AAT TGG ATG AGA CAG GCA CCT GGA CAG GGA CTC GAG TGG ATT GGA
TAA TTA ACC TAC TCT GTC CGT GGA CCT GTC CCT GAG CTC ACC TAA CCT
 I   N   W   M   R   Q   A   P   G   Q   G   L   E   W   I   G>

    630         640         650         660         670
     *           *           *           *           *
TGG ATT GAC CCT GGA TCT GGA AAT ACA AAG TAC AAT GAG AAG TTC AAG
ACC TAA CTG GGA CCT AGA CCT TTA TGT TTC ATG TTA CTC TTC AAG TTC
 W   I   D   P   G   S   G   N   T   K   Y   N   E   K   F   K>

        680         690         700         710         720
         *           *           *           *           *
GGA AGA GCA ACA CTG ACA GTG GAC ACA TCC ACG AAT ACC GCC TAC ATG
CCT TCT CGT TGT GAC TGT CAC CTG TGT AGG TGC TTA TGG CGG ATG TAC
 G   R   A   T   L   T   V   D   T   S   T   N   T   A   Y   M>

          730         740         750         760
           *           *           *           *
GAG CTG TCT TCT CTG AGA TCT GAG GAC ACA GCA TTC TAC TTC TGT GCA
CTC GAC AGA AGA GAC TCT AGA CTC CTG TGT CGT AAG ATG AAG ACA CGT
 E   L   S   S   L   R   S   E   D   T   A   F   Y   F   C   A>

770         780         790         800         810
 *           *           *           *           *
AGA GAG AAG ACC ACC TAC TAC TAC GCA ATG GAC TAC TGG GGA CAG GGA
TCT CTC TTC TGG TGG ATG ATG ATG CGT TAC CTG ATG ACC CCT GTC CCT
 R   E   K   T   T   Y   Y   Y   A   M   D   Y   W   G   Q   G>

  820         830         840         850         860
   *           *           *           *           *
ACA CTG GTG ACA GTG TCT TCT GCC TCA ACG AAG GGC CCG ACT AGT AAC
TGT GAC CAC TGT CAC AGA AGA CGG AGT TGC TTC CCG GGC TGA TCA TTG
 T   L   V   T   V   S   S   A   S   T   K   G   P   T   S   N>

    870         880         890         900         910
     *           *           *           *           *
TCC ATC ATG TAC TTC AGC CAC TTC GTG CCG GTC TTC CTG CCA GCG AAG
AGG TAG TAC ATG AAG TCG GTG AAG CAC GGC CAG AAG GAC GGT CGC TTC
 S   I   M   Y   F   S   H   F   V   P   V   F   L   P   A   K>
```

FIG. 5(contd.)

```
          920         930         940         950         960
           *           *           *           *           *
CCC ACC ACG ACG CCA GCG CCG CGA CCA CCA ACA CCG GCG CCC ACC ATC
GGG TGG TGC TGC GGT CGC GGC GCT GGT GGT TGT GGC CGC GGG TGG TAG
 P   T   T   T   P   A   P   R   P   P   T   P   A   P   T   I>

          970         980         990        1000
           *           *           *           *
GCG TCG CAG CCC CTG TCC CTG CGC CCA GAG GCG CAG AGC TTT GGC CTG
CGC AGC GTC GGG GAC AGG GAC GCG GGT CTC CGC GTC TCG AAA CCG GAC
 A   S   Q   P   L   S   L   R   P   E   A   Q   S   F   G   L>

1010        1020        1030        1040        1050
  *           *           *           *           *
CTG GAT CCC AAA CTC TGC TAC CTG CTG GAT GGA ATC CTC TTC ATC TAT
GAC CTA GGG TTT GAG ACG ATG GAC GAC CTA CCT TAG GAG AAG TAG ATA
 L   D   P   K   L   C   Y   L   L   D   G   I   L   F   I   Y>

          1060        1070        1080        1090        1100
           *           *           *           *           *
GGT GTC ATT CTC ACT GCC TTG TTC CTG AGA GTG AAG TTC AGC AGG AGC
CCA CAG TAA GAG TGA CGG AAC AAG GAC TCT CAC TTC AAG TCG TCC TCG
 G   V   I   L   T   A   L   F   L   R   V   K   F   S   R   S>

          1110        1120        1130        1140        1150
           *           *           *           *           *
GCA GAC GCC CCC GCG TAC CAG CAG GGC CAG AAC CAG CTC TAT AAC GAG
CGT CTG CGG GGG CGC ATG GTC GTC CCG GTC TTG GTC GAG ATA TTG CTC
 A   D   A   P   A   Y   Q   Q   G   Q   N   Q   L   Y   N   E>

          1160        1170        1180        1190        1200
           *           *           *           *           *
CTC AAT CTA GGA CGA AGA GAG GAG TAC GAT GTT TTG GAC AAG AGA CGT
GAG TTA GAT CCT GCT TCT CTC CTC ATG CTA CAA AAC CTG TTC TCT GCA
 L   N   L   G   R   R   E   E   Y   D   V   L   D   K   R   R>

          1210        1220        1230        1240
           *           *           *           *
GGC CGG GAC CCT GAG ATG GGG GGA AAG CCG AGA AGG AAG AAC CCT CAG
CCG GCC CTG GGA CTC TAC CCC CCT TTC GGC TCT TCC TTC TTG GGA GTC
 G   R   D   P   E   M   G   G   K   P   R   R   K   N   P   Q>

1250        1260        1270        1280        1290
  *           *           *           *           *
GAA GGC CTG TAC AAT GAA CTG CAG AAA GAT AAG ATG GCG GAG GCC TAC
CTT CCG GAC ATG TTA CTT GAC GTC TTT CTA TTC TAC CGC CTC CGG ATG
 E   G   L   Y   N   E   L   Q   K   D   K   M   A   E   A   Y>

          1300        1310        1320        1330        1340
           *           *           *           *           *
AGT GAG ATT GGG ATG AAA GGC GAG CGC CGG AGG GGC AAG GGG CAC GAT
TCA CTC TAA CCC TAC TTT CCG CTC GCG GCC TCC CCG TTC CCC GTG CTA
 S   E   I   G   M   K   G   E   R   R   R   G   K   G   H   D>

          1350        1360        1370        1380        1390
           *           *           *           *           *
GGC CTT TAC CAG GGT CTC AGT ACA GCC ACC AAG GAC ACC TAC GAC GCC
CCG GAA ATG GTC CCA GAG TCA TGT CGG TGG TTC CTG TGG ATG CTG CGG
 G   L   Y   Q   G   L   S   T   A   T   K   D   T   Y   D   A>
```

FIG.5(contd.)

```
1400          1410          1420          1430          1440
              *             *             *             *             *
CTT CAC ATG CAG GCC CTG CCC CCT CGC AGG AGT AAG AGG AGC AGG CTC
GAA GTG TAC GTC CGG GAC GGG GGA GCG TCC TCA TTC TCC TCG TCC GAG
 L   H   M   Q   A   L   P   P   R   R   S   K   R   S   R   L>

          1450          1460          1470          1480
              *             *             *             *
CTG CAC AGT GAC TAC ATG AAC ATG ACT CCC CGC CGC CCC GGG CCC ACC
GAC GTG TCA CTG ATG TAC TTG TAC TGA GGG GCG GCG GGG CCC GGG TGG
 L   H   S   D   Y   M   N   M   T   P   R   R   P   G   P   T>

1490          1500          1510          1520          1530
  *             *             *             *             *
CGC AAG CAT TAC CAG CCC TAT GCC CCA CCA CGC GAC TTC GCA GCC TAT
GCG TTC GTA ATG GTC GGG ATA CGG GGT GGT GCG CTG AAG CGT CGG ATA
 R   K   H   Y   Q   P   Y   A   P   P   R   D   F   A   A   Y>

  1540
    *
CGC TCC TGA
GCG AGG ACT
 R   S   *
```

FIG.6

SEQUENCE OF hCTMO1 /CD8 / CD28 RECOMBINANT CHIMERIC RECEPTOR

```
          10          20          30          40
           *           *           *           *
ATG TCT GTC CCC ACC CAA GTC CTC GGA CTC CTG CTG CTG TGG
TAC AGA CAG GGG TGG GTT CAG GAG CCT GAG GAC GAC GAC ACC
 M   S   V   P   T   Q   V   L   G   L   L   L   L   W>

      50          60          70          80
       *           *           *           *
CTT ACA GAT GCC AGA TGC GAT ATC CAG ATG ACT CAG AGT CCA
GAA TGT CTA CGG TCT ACG CTA TAG GTC TAC TGA GTC TCA GGT
 L   T   D   A   R   C   D   I   Q   M   T   Q   S   P>

     90          100         110         120
      *           *           *           *
AGT ACT CTC AGT GCC AGT GTA GGT GAT AGG GTC ACC ATC ACT
TCA TGA GAG TCA CGG TCA CAT CCA CTA TCC CAG TGG TAG TGA
 S   T   L   S   A   S   V   G   D   R   V   T   I   T>

  130         140         150         160
   *           *           *           *
TGT AGG AGT AGT AAA AGT CTC CTC CAT AGT AAC GGT GAC ACC
ACA TCC TCA TCA TTT TCA GAG GAG GTA TCA TTG CCA CTG TGG
 C   R   S   S   K   S   L   L   H   S   N   G   D   T>

170         180         190         200         210
 *           *           *           *           *
TTC CTC TAT TGG TTC CAG CAG AAA CCA GGT AAA GCC CCA AAG
AAG GAG ATA ACC AAG GTC GTC TTT GGT CCA TTT CGG GGT TTC
 F   L   Y   W   F   Q   Q   K   P   G   K   A   P   K>

          220         230         240         250
           *           *           *           *
CTC CTC ATG TAT AGG ATG AGT AAC CTC GCC AGT GGT GTA CCA
GAG GAG TAC ATA TCC TAC TCA TTG GAG CGG TCA CCA CAT GGT
 L   L   M   Y   R   M   S   N   L   A   S   G   V   P>

      260         270         280         290
       *           *           *           *
TCT AGA TTC AGT GGT AGT GGT AGT GGT ACT GAG TTC ACT CTC
AGA TCT AAG TCA CCA TCA CCA TCA CCA TGA CTC AAG TGA GAG
 S   R   F   S   G   S   G   S   G   T   E   F   T   L>

     300         310         320         330
      *           *           *           *
ACT ATC AGT AGT CTC CAG CCA GAT GAT TTC GCC ACT TAT TAT
TGA TAG TCA TCA GAG GTC GGT CTA CTA AAG CGG TGA ATA ATA
 T   I   S   S   L   Q   P   D   D   F   A   T   Y   Y>

  340         350         360         370
   *           *           *           *
TGT ATG CAG CAT CTC GAA TAT CCA TTC ACT TTC GGT CAG GGT
ACA TAC GTC GTA GAG CTT ATA GGT AAG TGA AAG CCA GTC CCA
 C   M   Q   H   L   E   Y   P   F   T   F   G   Q   G>
```

FIG.6(contd.)

```
380                 390                 400                 410                 420
 *                   *                   *                   *                   *
ACT AAA GTA GAA GTA AAA CGT ACG GGT GGC GGA GGG TCA GGT
TGA TTT CAT CTT CAT TTT GCA TGC CCA CCG CCT CCC AGT CCA
 T   K   V   E   V   K   R   T   G   G   G   G   S   G>

          430                 440                 450                 460
           *                   *                   *                   *
GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA
CCG CCT CCC AGT CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT
 G   G   G   S   G   G   G   G   S   G   G   G   G   S>

        470                 480                 490                 500
         *                   *                   *                   *
GGT GGC GGA GGG TCA CAG ATT CAG CTG GTG CAG TCT GGA GCA
CCA CCG CCT CCC AGT GTC TAA GTC GAC CAC GTC AGA CCT CGT
 G   G   G   G   S   Q   I   Q   L   V   Q   S   G   A>

    510                 520                 530                 540
     *                   *                   *                   *
GAG GTG AAG AAG CCT GGA TCT TCT GTG AAG GTG TCT TGT AAG
CTC CAC TTC TTC GGA CCT AGA AGA CAC TTC CAC AGA ACA TTC
 E   V   K   K   P   G   S   S   V   K   V   S   C   K>

  550                 560                 570                 580
   *                   *                   *                   *
GCA TCT GGA TAC ACC TTC ACC GAC TAC TAC ATT AAT TGG ATG
CGT AGA CCT ATG TGG AAG TGG CTG ATG ATG TAA TTA ACC TAC
 A   S   G   Y   T   F   T   D   Y   Y   I   N   W   M>

590                 600                 610                 620                 630
 *                   *                   *                   *                   *
AGA CAG GCA CCT GGA CAG GGA CTC GAG TGG ATT GGA TGG ATT
TCT GTC CGT GGA CCT GTC CCT GAG CTC ACC TAA CCT ACC TAA
 R   Q   A   P   G   Q   G   L   E   W   I   G   W   I>

          640                 650                 660                 670
           *                   *                   *                   *
GAC CCT GGA TCT GGA AAT ACA AAG TAC AAT GAG AAG TTC AAG
CTG GGA CCT AGA CCT TTA TGT TTC ATG TTA CTC TTC AAG TTC
 D   P   G   S   G   N   T   K   Y   N   E   K   F   K>

        680                 690                 700                 710
         *                   *                   *                   *
GGA AGA GCA ACA CTG ACA GTG GAC ACA TCC ACG AAT ACC GCC
CCT TCT CGT TGT GAC TGT CAC CTG TGT AGG TGC TTA TGG CGG
 G   R   A   T   L   T   V   D   T   S   T   N   T   A>

    720                 730                 740                 750
     *                   *                   *                   *
TAC ATG GAG CTG TCT TCT CTG AGA TCT GAG GAC ACA GCA TTC
ATG TAC CTC GAC AGA AGA GAC TCT AGA CTC CTG TGT CGT AAG
 Y   M   E   L   S   S   L   R   S   E   D   T   A   F>

  760                 770                 780                 790
   *                   *                   *                   *
TAC TTC TGT GCA AGA GAG AAG ACC ACC TAC TAC TAC GCA ATG
ATG AAG ACA CGT TCT CTC TTC TGG TGG ATG ATG ATG CGT TAC
 Y   F   C   A   R   E   K   T   T   Y   Y   Y   A   M>
```

FIG.6(contd.)

```
800          810          820          830          840
 *            *            *            *            *
GAC TAC TGG GGA CAG GGA ACA CTG GTG ACA GTG TCT TCT GCC
CTG ATG ACC CCT GTC CCT TGT GAC CAC TGT CAC AGA AGA CGG
 D   Y   W   G   Q   G   T   L   V   T   V   S   S   A>

          850          860          870          880
           *            *            *            *
TCA ACG AAG GGC CCG ACT AGT AAC TCC ATC ATG TAC TTC AGC
AGT TGC TTC CCG GGC TGA TCA TTG AGG TAG TAC ATG AAG TCG
 S   T   K   G   P   T   S   N   S   I   M   Y   F   S>

        890          900          910          920
         *            *            *            *
CAC TTC GTG CCG GTC TTC CTG CCA GCG AAG CCC ACC ACG ACG
GTG AAG CAC GGC CAG AAG GAC GGT CGC TTC GGG TGG TGC TGC
 H   F   V   P   V   F   L   P   A   K   P   T   T   T

    930          940          950          960
     *            *            *            *
CCA GCG CCG CGA CCA CCA ACA CCG GCG CCC ACC ATC GCG TCG
GGT CGC GGC GCT GGT GGT TGT GGC CGC GGG TGG TAG CGC AGC
 P   A   P   R   P   P   T   P   A   P   T   I   A   S>

   970          980          990          1000
    *            *            *            *
CAG CCC CTG TCC CTG CGC CCA GAG GCG GGA TCC AAG CCC TTT
GTC GGG GAC AGG GAC GCG GGT CTC CGC CCT AGG TTC GGG AAA
 Q   P   L   S   L   R   P   E   A   G   S   K   P   F>

1010         1020         1030         1040         1050
 *            *            *            *            *
TGG GTG CTG GTG GTG GTT GGT GGA GTC CTG GCT TGC TAT AGC
ACC CAC GAC CAC CAC CAA CCA CCT CAG GAC CGA ACG ATA TCG
 W   V   L   V   V   V   G   G   V   L   A   C   Y   S>

          1060         1070         1080         1090
           *            *            *            *
TTG CTA GTA ACA GTG GCC TTT ATT ATT TTC TGG GTG AGG AGT
AAC GAT CAT TGT CAC CGG AAA TAA TAA AAG ACC CAC TCC TCA
 L   L   V   T   V   A   F   I   I   F   W   V   R   S>

        1100         1110         1120         1130
         *            *            *            *
AAG AGG AGC AGG CTC CTG CAC AGT GAC TAC ATG AAC ATG ACT
TTC TCC TCG TCC GAG GAC GTG TCA CTG ATG TAC TTG TAC TGA
 K   R   S   R   L   L   H   S   D   Y   M   N   M   T>

   1140         1150         1160         1170
    *            *            *            *
CCC CGC CGC CCC GGG CCC ACC CGC AAG CAT TAC CAG CCC TAT
GGG GCG GCG GGG CCC GGG TGG GCG TTC GTA ATG GTC GGG ATA
 P   R   R   P   G   P   T   R   K   H   Y   Q   P   Y>

 1180         1190         1200         1210
  *            *            *            *
GCC CCA CCA CGC GAC TTC GCA GCC TAT CGC TCC TGA
CGG GGT GGT GCG CTG AAG CGT CGG ATA GCG AGG ACT
 A   P   P   R   D   F   A   A   Y   R   S   *
```

FIG. 7

SEQUENCE OF hCTM01 / G1 / ZETA RECOMBINANT CHIMERIC RECEPTOR

```
          10          20          30          40
          *           *           *           *
ATG TCT GTC CCC ACC CAA GTC CTC GGA CTC CTG CTG CTG TGG CTT ACA
TAC AGA CAG GGG TGG GTT CAG GAG CCT GAG GAC GAC GAC ACC GAA TGT
 M   S   V   P   T   Q   V   L   G   L   L   L   L   W   L   T>

50          60          70          80          90
*           *           *           *           *
GAT GCC AGA TGC GAT ATC CAG ATG ACT CAG AGT CCA AGT ACT CTC AGT
CTA CGG TCT ACG CTA TAG GTC TAC TGA GTC TCA GGT TCA TGA GAG TCA
 D   A   R   C   D   I   Q   M   T   Q   S   P   S   T   L   S>

  100         110         120         130         140
   *           *           *           *           *
GCC AGT GTA GGT GAT AGG GTC ACC ATC ACT TGT AGG AGT AGT AAA AGT
CGG TCA CAT CCA CTA TCC CAG TGG TAG TGA ACA TCC TCA TCA TTT TCA
 A   S   V   G   D   R   V   T   I   T   C   R   S   S   K   S>

    150         160         170         180         190
     *           *           *           *           *
CTC CTC CAT AGT AAC GGT GAC ACC TTC CTC TAT TGG TTC CAG CAG AAA
GAG GAG GTA TCA TTG CCA CTG TGG AAG GAG ATA ACC AAG GTC GTC TTT
 L   L   H   S   N   G   D   T   F   L   Y   W   F   Q   Q   K>

        200         210         220         230         240
         *           *           *           *           *
CCA GGT AAA GCC CCA AAG CTC CTC ATG TAT AGG ATG AGT AAC CTC GCC
GGT CCA TTT CGG GGT TTC GAG GAG TAC ATA TCC TAC TCA TTG GAG CGG
 P   G   K   A   P   K   L   L   M   Y   R   M   S   N   L   A>

          250         260         270         280
           *           *           *           *
AGT GGT GTA CCA TCT AGA TTC AGT GGT AGT GGT AGT GGT ACT GAG TTC
TCA CCA CAT GGT AGA TCT AAG TCA CCA TCA CCA TCA CCA TGA CTC AAG
 S   G   V   P   S   R   F   S   G   S   G   S   G   T   E   F>

290         300         310         320         330
*           *           *           *           *
ACT CTC ACT ATC AGT AGT CTC CAG CCA GAT GAT TTC GCC ACT TAT TAT
TGA GAG TGA TAG TCA TCA GAG GTC GGT CTA CTA AAG CGG TGA ATA ATA
 T   L   T   I   S   S   L   Q   P   D   D   F   A   T   Y   Y>

  340         350         360         370         380
   *           *           *           *           *
TGT ATG CAG CAT CTC GAA TAT CCA TTC ACT TTC GGT CAG GGT ACT AAA
ACA TAC GTC GTA GAG CTT ATA GGT AAG TGA AAG CCA GTC CCA TGA TTT
 C   M   Q   H   L   E   Y   P   F   T   F   G   Q   G   T   K>

    390         400         410         420         430
     *           *           *           *           *
GTA GAA GTA AAA CCT ACG GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA
CAT CTT CAT TTT GCA TGC CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT
 V   E   V   K   R   T   G   G   G   G   S   G   G   G   G   S>
```

FIG. 7 (contd.)

```
       440          450          460          470          480
        *            *            *            *            *
GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA CAG
CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT GTC
 G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   Q>

         490          500          510          520
          *            *            *            *
ATT CAG CTG GTG CAG TCT GGA GCA GAG GTG AAG AAG CCT GGA TCT TCT
TAA GTC GAC CAC GTC AGA CCT CGT CTC CAC TTC TTC GGA CCT AGA AGA
 I   Q   L   V   Q   S   G   A   E   V   K   K   P   G   S   S>

530          540          550          560          570
 *            *            *            *            *
GTG AAG GTG TCT TGT AAG GCA TCT GGA TAC ACC TTC ACC GAC TAC TAC
CAC TTC CAC AGA ACA TTC CGT AGA CCT ATG TGG AAG TGG CTG ATG ATG
 V   K   V   S   C   K   A   S   G   Y   T   F   T   D   Y   Y>

  580          590          600          610          620
   *            *            *            *            *
ATT AAT TGG ATG AGA CAG GCA CCT GGA CAG GGA CTC GAG TGG ATT GGA
TAA TTA ACC TAC TCT GTC CGT GGA CCT GTC CCT GAG CTC ACC TAA CCT
 I   N   W   M   R   Q   A   P   G   Q   G   L   E   W   I   G>

    630          640          650          660          670
     *            *            *            *            *
TGG ATT GAC CCT GGA TCT GGA AAT ACA AAG TAC AAT GAG AAG TTC AAG
ACC TAA CTG GGA CCT AGA CCT TTA TGT TTC ATG TTA CTC TTC AAG TTC
 W   I   D   P   G   S   G   N   T   K   Y   N   E   K   F   K>

       680          690          700          710          720
        *            *            *            *            *
GGA AGA GCA ACA CTG ACA GTG GAC ACA TCC ACG AAT ACC GCC TAC ATG
CCT TCT CGT TGT GAC TGT CAC CTG TGT AGG TGC TTA TGG CGG ATG TAC
 G   R   A   T   L   T   V   D   T   S   T   N   T   A   Y   M>

         730          740          750          760
          *            *            *            *
GAG CTG TCT TCT CTG AGA TCT GAG GAC ACA GCA TTC TAC TTC TGT GCA
CTC GAC AGA AGA GAC TCT AGA CTC CTG TGT CGT AAG ATG AAG ACA CGT
 E   L   S   S   L   R   S   E   D   T   A   F   Y   F   C   A>

770          780          790          800          810
 *            *            *            *            *
AGA GAG AAG ACC ACC TAC TAC TAC GCA ATG GAC TAC TGG GGA CAG GGA
TCT CTC TTC TGG TGG ATG ATG ATG CGT TAC CTG ATG ACC CCT GTC CCT
 R   E   K   T   T   Y   Y   Y   A   M   D   Y   W   G   Q   G>

  820          830          840          850          860
   *            *            *            *            *
ACA CTG GTG ACA GTG TCT TCT GCC TCA ACG AAG GGC CCG ACT AGT GAC
TGT GAC CAC TGT CAC AGA AGA CGG AGT TGC TTC CCG GGC TGA TCA CTG
 T   L   V   T   V   S   S   A   S   T   K   G   P   T   S   D>

    870          880          890          900          910
     *            *            *            *            *
AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA
TTT TGA GTG TGT ACG GGT GGC ACG GGT CGT GGA CTT GAG GAC CCC CCT
 K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G>
```

FIG. 7 (contd.)

```
          920         930         940         950         960
           *           *           *           *           *
CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC
GGC AGT CAG AAG GAG AAG GGG GGT TTT GGG TTC CTG TGG GAG TAC TAG
 P   S   V   F   L   F   P   P   K   P   K   D   T   L   M   I>

              970         980         990        1000
               *           *           *           *
TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA
AGG GCC TGG GGA CTC CAG TGT ACG CAC CAC CAC CTG CAC TCG GTG CTT
 S   R   T   P   E   V   T   C   V   V   V   D   V   S   H   E>

1010        1020        1030        1040        1050
  *           *           *           *           *
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT
CTG GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG CCG CAC CTC CAC GTA
 D   P   E   V   K   F   N   W   Y   V   D   G   V   E   V   H>

  1060        1070        1080        1090        1100
    *           *           *           *           *
AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT
TTA CGG TTC TGT TTC GGC GCC CTC CTC GTC ATG TTG TCG TGC ATG GCA
 N   A   K   T   K   P   R   E   E   Q   Y   N   S   T   Y   R>

    1110        1120        1130        1140        1150
      *           *           *           *           *
GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG
CAC CAG TCG CAG GAG TGG CAG GAC GTG GTC CTG ACC GAC TTA CCG TTC
 V   V   S   V   L   T   V   L   H   Q   D   W   L   N   G   K>

        1160        1170        1180        1190        1200
          *           *           *           *           *
GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG
CTC ATG TTC ACG TTC CAG AGG TTG TTT CGG GAG GGT CGG GGG TAG CTC
 E   Y   K   C   K   V   S   N   K   A   L   P   A   P   I   E>

              1210        1220        1230        1240
               *           *           *           *
AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC
TTT TGG TAG AGG TTT CGG TTT CCC GTC GGG GCT CTT GGT GTC CAC ATG
 K   T   I   S   K   A   K   G   Q   P   R   E   P   Q   V   Y>

1250        1260        1270        1280        1290
  *           *           *           *           *
ACC CTG CCC CCA TCC CGG GAG GAG ATG ACC AAG AAC CAG GTC AGC CTG
TGG GAC GGG GGT AGG GCC CTC CTC TAC TGG TTC TTG GTC CAG TCG GAC
 T   L   P   P   S   R   E   E   M   T   K   N   Q   V   S   L>

  1300        1310        1320        1330        1340
    *           *           *           *           *
ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG
TGG ACG GAC CAG TTT CCG AAG ATA GGG TCG CTG TAG CGG CAC CTC ACC
 T   C   L   V   K   G   F   Y   P   S   D   I   A   V   E   W>

    1350        1360        1370        1380        1390
      *           *           *           *           *
GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG
CTC TCG TTA CCC GTC GGC CTC TTG TTG ATG TTC TGG TGC GGA GGG CAC
 E   S   N   G   Q   P   E   N   N   Y   K   T   T   P   P   V>

        1400        1410        1420        1430        1440
          *           *           *           *           *
CTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC
GAC CTG AGG CTG CCG AGG AAG AAG GAG ATG TCG TTC GAG TGG CAC CTG
 L   D   S   D   G   S   F   F   L   Y   S   K   L   T   V   D>
```

21/40 FIG. 7(contd.)

```
          1450        1460        1470        1480
            *           *           *           *
AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAT
TTC TCG TCC ACC GTC GTC CCC TTG CAG AAG AGT ACG AGG CAC TAC GTA
 K   S   R   W   Q   Q   G   N   V   F   S   C   S   V   M   H>

1490        1500        1510        1520        1530
  *           *           *           *           *
GAG GCT CTG CAC AAC CAC TAC ACG CAG AAG AGC CTC TCC CTG TCT CCG
CTC CGA GAC GTG TTG GTG ATG TGC GTC TTC TCG GAG AGG GAC AGA GGC
 E   A   L   H   N   H   Y   T   Q   K   S   L   S   L   S   P>

  1540        1550        1560        1570        1580
    *           *           *           *           *
GGT AAA CTG GAT CCC AAA CTC TGC TAC CTG CTG GAT GGA ATC CTC TTC
CCA TTT GAC CTA GGG TTT GAG ACG ATG GAC GAC CTA CCT TAG GAG AAG
 G   K   L   D   P   K   L   C   Y   L   L   D   G   I   L   F>

    1590        1600        1610        1620        1630
      *           *           *           *           *
ATC TAT GGT GTC ATT CTC ACT GCC TTG TTC CTG AGA GTG AAG TTC AGC
TAG ATA CCA CAG TAA GAG TGA CGG AAC AAG GAC TCT CAC TTC AAG TCG
 I   Y   G   V   I   L   T   A   L   F   L   R   V   K   F   S>

        1640        1650        1660        1670        1680
          *           *           *           *           *
AGG AGC GCA GAC GCC CCC GCG TAC CAG CAG GGC CAG AAC CAG CTC TAT
TCC TCG CGT CTG CGG GGG CGC ATG GTC GTC CCG GTC TTG GTC GAG ATA
 R   S   A   D   A   P   A   Y   Q   Q   G   Q   N   Q   L   Y>

          1690        1700        1710        1720
            *           *           *           *
AAC GAG CTC AAT CTA GGA CGA AGA GAG GAG TAC GAT GTT TTG GAC AAG
TTG CTC GAG TTA GAT CCT GCT TCT CTC CTC ATG CTA CAA AAC CTG TTC
 N   E   L   N   L   G   R   R   E   E   Y   D   V   L   D   K>

1730        1740        1750        1760        1770
  *           *           *           *           *
AGA CGT GGC CGG GAC CCT GAG ATG GGG GGA AAG CCG AGA AGG AAG AAC
TCT GCA CCG GCC CTG GGA CTC TAC CCC CCT TTC GGC TCT TCC TTC TTG
 R   R   G   R   D   P   E   M   G   G   K   P   R   R   K   N>

  1780        1790        1800        1810        1820
    *           *           *           *           *
CCT CAG GAA GGC CTG TAC AAT GAA CTG CAG AAA GAT AAG ATG GCG GAG
GGA GTC CTT CCG GAC ATG TTA CTT GAC GTC TTT CTA TTC TAC CGC CTC
 P   Q   E   G   L   Y   N   E   L   Q   K   D   K   M   A   E>

    1830        1840        1850        1860        1870
      *           *           *           *           *
GCC TAC AGT GAG ATT GGG ATG AAA GGC GAG CGC CGG AGG GGC AAG GGG
CGG ATG TCA CTC TAA CCC TAC TTT CCG CTC GCG GCC TCC CCG TTC CCC
 A   Y   S   E   I   G   M   K   G   E   R   R   R   G   K   G>

        1880        1890        1900        1910        1920
          *           *           *           *           *
CAC GAT GGC CTT TAC CAG GGT CTC AGT ACA GCC ACC AAG GAC ACC TAC
GTG CTA CCG GAA ATG GTC CCA GAG TCA TGT CGG TGG TTC CTG TGG ATG
 H   D   G   L   Y   Q   G   L   S   T   A   T   K   D   T   Y>

          1930        1940        1950
            *           *           *
GAC GCC CTT CAC ATG CAG GCC CTG CCC CCT CGC TAA
CTG CGG GAA GTG TAC GTC CGG GAC GGG GGA GCG ATT
 D   A   L   H   M   Q   A   L   P   P   R   *
```

FIG. 8

SEQUENCE OF hCTMO1/G1/ZETA-CD28 FUSION RECOMBINANT CHIMERIC RECEPTOR

```
          10          20          30          40
          *           *           *           *
ATG TCT GTC CCC ACC CAA GTC CTC GGA CTC CTG CTG CTG TGG CTT ACA
TAC AGA CAG GGG TGG GTT CAG GAG CCT GAG GAC GAC GAC ACC GAA TGT
 M   S   V   P   T   Q   V   L   G   L   L   L   L   W   L   T>

50          60          70          80          90
*           *           *           *           *
GAT GCC AGA TGC GAT ATC CAG ATG ACT CAG AGT CCA AGT ACT CTC AGT
CTA CGG TCT ACG CTA TAG GTC TAC TGA GTC TCA GGT TCA TGA GAG TCA
 D   A   R   C   D   I   Q   M   T   Q   S   P   S   T   L   S>

100         110         120         130         140
*           *           *           *           *
GCC AGT GTA GGT GAT AGG GTC ACC ATC ACT TGT AGG AGT AGT AAA AGT
CGG TCA CAT CCA CTA TCC CAG TGG TAG TGA ACA TCC TCA TCA TTT TCA
 A   S   V   G   D   R   V   T   I   T   C   R   S   S   K   S>

150         160         170         180         190
*           *           *           *           *
CTC CTC CAT AGT AAC GGT GAC ACC TTC CTC TAT TGG TTC CAG CAG AAA
GAG GAG GTA TCA TTG CCA CTG TGG AAG GAG ATA ACC AAG GTC GTC TTT
 L   L   H   S   N   G   D   T   F   L   Y   W   F   Q   Q   K>

200         210         220         230         240
*           *           *           *           *
CCA GGT AAA GCC CCA AAG CTC CTC ATG TAT AGG ATG AGT AAC CTC GCC
GGT CCA TTT CGG GGT TTC GAG GAG TAC ATA TCC TAC TCA TTG GAG CGG
 P   G   K   A   P   K   L   L   M   Y   R   M   S   N   L   A>

          250         260         270         280
          *           *           *           *
AGT GGT GTA CCA TCT AGA TTC AGT GGT AGT GGT AGT GGT ACT GAG TTC
TCA CCA CAT GGT AGA TCT AAG TCA CCA TCA CCA TCA CCA TGA CTC AAG
 S   G   V   P   S   R   F   S   G   S   G   S   G   T   E   F>

290         300         310         320         330
*           *           *           *           *
ACT CTC ACT ATC AGT AGT CTC CAG CCA GAT GAT TTC GCC ACT TAT TAT
TGA GAG TGA TAG TCA TCA GAG GTC GGT CTA CTA AAG CGG TGA ATA ATA
 T   L   T   I   S   S   L   Q   P   D   D   F   A   T   Y   Y>

340         350         360         370         380
*           *           *           *           *
TGT ATG CAG CAT CTC GAA TAT CCA TTC ACT TTC GGT CAG GGT ACT AAA
ACA TAC GTC GTA GAG CTT ATA GGT AAG TGA AAG CCA GTC CCA TGA TTT
 C   M   Q   H   L   E   Y   P   F   T   F   G   Q   G   T   K>

390         400         410         420         430
*           *           *           *           *
GTA GAA GTA AAA CGT ACG GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA
CAT CTT CAT TTT GCA TGC CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT
 V   E   V   K   R   T   G   G   G   G   S   G   G   G   G   S>
```

FIG. 8(contd.)

```
        440         450         460         470         480
         *           *           *           *           *
GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA CAG
CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT GTC
 G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   Q>

            490         500         510         520
             *           *           *           *
ATT CAG CTG GTG CAG TCT GGA GCA GAG GTG AAG AAG CCT GGA TCT TCT
TAA GTC GAC CAC GTC AGA CCT CGT CTC CAC TTC TTC GGA CCT AGA AGA
 I   Q   L   V   Q   S   G   A   E   V   K   K   P   G   S   S>

530         540         550         560         570
 *           *           *           *           *
GTG AAG GTG TCT TGT AAG GCA TCT GGA TAC ACC TTC ACC GAC TAC TAC
CAC TTC CAC AGA ACA TTC CGT AGA CCT ATG TGG AAG TGG CTG ATG ATG
 V   K   V   S   C   K   A   S   G   Y   T   F   T   D   Y   Y>

  580         590         600         610         620
   *           *           *           *           *
ATT AAT TGG ATG AGA CAG GCA CCT GGA CAG GGA CTC GAG TGG ATT GGA
TAA TTA ACC TAC TCT GTC CGT GGA CCT GTC CCT GAG CTC ACC TAA CCT
 I   N   W   M   R   Q   A   P   G   Q   G   L   E   W   I   G>

    630         640         650         660         670
     *           *           *           *           *
TGG ATT GAC CCT GGA TCT GGA AAT ACA AAG TAC AAT GAG AAG TTC AAG
ACC TAA CTG GGA CCT AGA CCT TTA TGT TTC ATG TTA CTC TTC AAG TTC
 W   I   D   P   G   S   G   N   T   K   Y   N   E   K   F   K>

        680         690         700         710         720
         *           *           *           *           *
GGA AGA GCA ACA CTG ACA GTG GAC ACA TCC ACG AAT ACC GCC TAC ATG
CCT TCT CGT TGT GAC TGT CAC CTG TGT AGG TGC TTA TGG CGG ATG TAC
 G   R   A   T   L   T   V   D   T   S   T   N   T   A   Y   M>

            730         740         750         760
             *           *           *           *
GAG CTG TCT TCT CTG AGA TCT GAG GAC ACA GCA TTC TAC TTC TGT GCA
CTC GAC AGA AGA GAC TCT AGA CTC CTG TGT CGT AAG ATG AAG ACA CGT
 E   L   S   S   L   R   S   E   D   T   A   F   Y   F   C   A>

770         780         790         800         810
 *           *           *           *           *
AGA GAG AAG ACC ACC TAC TAC TAC GCA ATG GAC TAC TGG GGA CAG GGA
TCT CTC TTC TGG TGG ATG ATG ATG CGT TAC CTG ATG ACC CCT GTC CCT
 R   E   K   T   T   Y   Y   Y   A   M   D   Y   W   G   Q   G>

  820         830         840         850         860
   *           *           *           *           *
ACA CTG GTG ACA GTG TCT TCT GCC TCA ACG AAG GGC CCG ACT AGT GAC
TGT GAC CAC TGT CAC AGA AGA CGG AGT TGC TTC CCG GGC TGA TCA CTG
 T   L   V   T   V   S   S   A   S   T   K   G   P   T   S   D>

    870         880         890         900         910
     *           *           *           *           *
AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA
TTT TGA GTG TGT ACG GGT GGC ACG GGT CGT GGA CTT GAG GAC CCC CCT
 K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G>
```

FIG. 8(contd.)

```
       920         930         940         950         960
        *           *           *           *           *
CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC
GGC AGT CAG AAG GAG AAG GGG GGT TTT GGG TTC CTG TGG GAG TAC TAG
 P   S   V   F   L   F   P   P   K   P   K   D   T   L   M   I>

           970         980         990        1000
            *           *           *           *
TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA
AGG GCC TGG GGA CTC CAG TGT ACG CAC CAC CAC CTG CAC TCG GTG CTT
 S   R   T   P   E   V   T   C   V   V   V   D   V   S   H   E>

1010        1020        1030        1040        1050
  *           *           *           *           *
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT
CTG GGA CTC CAG TTC AAG TTG ACC ATG CAC CTG CCG CAC CTC CAC GTA
 D   P   E   V   K   F   N   W   Y   V   D   G   V   E   V   H>

 1060        1070        1080        1090        1100
    *           *           *           *           *
AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGT
TTA CGG TTC TGT TTC GGC GCC CTC CTC GTC ATG TTG TCG TGC ATG GCA
 N   A   K   T   K   P   R   E   E   Q   Y   N   S   T   Y   R>

   1110        1120        1130        1140        1150
      *           *           *           *           *
GTG GTC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG
CAC CAG TCG CAG GAG TGG CAG GAC GTG GTC CTG ACC GAC TTA CCG TTC
 V   V   S   V   L   T   V   L   H   Q   D   W   L   N   G   K>

      1160        1170        1180        1190        1200
        *           *           *           *           *
GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG
CTC ATG TTC ACG TTC CAG AGG TTG TTT CGG GAG GGT CGG GGG TAG CTC
 E   Y   K   C   K   V   S   N   K   A   L   P   A   P   I   E>

           1210        1220        1230        1240
            *           *           *           *
AAA ACC ATC TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC
TTT TGG TAG AGG TTT CGG TTT CCC GTC GGG GCT CTT GGT GTC CAC ATG
 K   T   I   S   K   A   K   G   Q   P   R   E   P   Q   V   Y>

1250        1260        1270        1280        1290
  *           *           *           *           *
ACC CTG CCC CCA TCC CGG GAG GAG ATG ACC AAG AAC CAG GTC AGC CTG
TGG GAC GGG GGT AGG GCC CTC CTC TAC TGG TTC TTG GTC CAG TCG GAC
 T   L   P   P   S   R   E   E   M   T   K   N   Q   V   S   L>

 1300        1310        1320        1330        1340
    *           *           *           *           *
ACC TGC CTG GTC AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG
TGG ACG GAC CAG TTT CCG AAG ATA GGG TCG CTG TAG CGG CAC CTC ACC
 T   C   L   V   K   G   F   Y   P   S   D   I   A   V   E   W>

   1350        1360        1370        1380        1390
      *           *           *           *           *
GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG
CTC TCG TTA CCC GTC GGC CTC TTG TTG ATG TTC TGG TGC GGA GGG CAC
 E   S   N   G   Q   P   E   N   N   Y   K   T   T   P   P   V>

      1400        1410        1420        1430        1440
        *           *           *           *           *
CTG GAC TCC GAC GGC TCC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC
GAC CTG AGG CTG CCG AGG AAG AAG GAG ATG TCG TTC GAG TGG CAC CTG
 L   D   S   D   G   S   F   F   L   Y   S   K   L   T   V   D>
```

25/40

FIG.8(contd.)



```
          1930          1940          1950          1960
            *             *             *             *
GAC GCC CTT CAC ATG CAG GCC CTG CCC CCT CGC AGG AGT AAG AGG AGC
CTG CGG GAA GTG TAC GTC CGG GAC GGG GGA GCG TCC TCA TTC TCC TCG
 D   A   L   H   M   Q   A   L   P   P   R   R   S   K   R   S>

1970          1980          1990          2000          2010
  *             *             *             *             *
AGG CTC CTG CAC AGT GAC TAC ATG AAC ATG ACT CCC CGC CGC CCC GGG
TCC GAG GAC GTG TCA CTG ATG TAC TTG TAC TGA GGG GCG GCG GGG CCC
 R   L   L   H   S   D   Y   M   N   M   T   P   R   R   P   G>

 2020          2030          2040          2050          2060
   *             *             *             *             *
CCC ACC CGC AAG CAT TAC CAG CCC TAT GCC CCA CCA CGC GAC TTC GCA
GGG TGG GCG TTC GTA ATG GTC GGG ATA CGG GGT GGT GCG CTG AAG CGT
 P   T   R   K   H   Y   Q   P   Y   A   P   P   R   D   F   A>

   2070
     *
GCC TAT CGC TCC TGA
CGG ATA GCG AGG ACT
 A   Y   R   S   *
```

FIG. 8 (contd.)

FIG.9

SEQUENCE OF hCTMO1 / h / CD28 RECOMBINANT CHIMERIC RECEPTOR

```
          10          20          30          40
          *           *           *           *
ATG TCT GTC CCC ACC CAA GTC CTC GGA CTC CTG CTG CTG TGG CTT ACA
TAC AGA CAG GGG TGG GTT CAG GAG CCT GAG GAC GAC GAC ACC GAA TGT
 M   S   V   P   T   Q   V   L   G   L   L   L   L   W   L   T>

50          60          70          80          90
*           *           *           *           *
GAT GCC AGA TGC GAT ATC CAG ATG ACT CAG AGT CCA AGT ACT CTC AGT
CTA CGG TCT ACG CTA TAG GTC TAC TGA GTC TCA GGT TCA TGA GAG TCA
 D   A   R   C   D   I   Q   M   T   Q   S   P   S   T   L   S>

 100         110         120         130         140
  *           *           *           *           *
GCC AGT GTA GGT GAT AGG GTC ACC ATC ACT TGT AGG AGT AGT AAA AGT
CGG TCA CAT CCA CTA TCC CAG TGG TAG TGA ACA TCC TCA TCA TTT TCA
 A   S   V   G   D   R   V   T   I   T   C   R   S   S   K   S>

    150         160         170         180         190
     *           *           *           *           *
CTC CTC CAT AGT AAC GGT GAC ACC TTC CTC TAT TGG TTC CAG CAG AAA
GAG GAG GTA TCA TTG CCA CTG TGG AAG GAG ATA ACC AAG GTC GTC TTT
 L   L   H   S   N   G   D   T   F   L   Y   W   F   Q   Q   K>

       200         210         220         230         240
        *           *           *           *           *
CCA GGT AAA GCC CCA AAG CTC CTC ATG TAT AGG ATG AGT AAC CTC GCC
GGT CCA TTT CGG GGT TTC GAG GAG TAC ATA TCC TAC TCA TTG GAG CGG
 P   G   K   A   P   K   L   L   M   Y   R   M   S   N   L   A>

          250         260         270         280
           *           *           *           *
AGT GGT GTA CCA TCT AGA TTC AGT GGT AGT GGT AGT GGT ACT GAG TTC
TCA CCA CAT GGT AGA TCT AAG TCA CCA TCA CCA TCA CCA TGA CTC AAG
 S   G   V   P   S   R   F   S   G   S   G   S   G   T   E   F>

290         300         310         320         330
*           *           *           *           *
ACT CTC ACT ATC AGT AGT CTC CAG CCA GAT GAT TTC GCC ACT TAT TAT
TGA GAG TGA TAG TCA TCA GAG GTC GGT CTA CTA AAG CGG TGA ATA ATA
 T   L   T   I   S   S   L   Q   P   D   D   F   A   T   Y   Y>

 340         350         360         370         380
  *           *           *           *           *
TGT ATG CAG CAT CTC GAA TAT CCA TTC ACT TTC GGT CAG GGT ACT AAA
ACA TAC GTC GTA GAG CTT ATA GGT AAG TGA AAG CCA GTC CCA TGA TTT
 C   M   Q   H   L   E   Y   P   F   T   F   G   Q   G   T   K>

    390         400         410         420         430
     *           *           *           *           *
GTA GAA GTA AAA CGT ACG GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA
CAT CTT CAT TTT GCA TGC CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT
 V   E   V   K   R   T   G   G   G   G   S   G   G   G   G   S>
```

28/40

FIG. 9 (contd.)

```
      440         450         460         470         480
       *           *           *           *           *
GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA GGT GGC GGA GGG TCA CAG
CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT CCA CCG CCT CCC AGT GTC
 G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   Q>

          490         500         510         520
           *           *           *           *
ATT CAG CTG GTG CAG TCT GGA GCA GAG GTG AAG AAG CCT GGA TCT TCT
TAA GTC GAC CAC GTC AGA CCT CGT CTC CAC TTC TTC GGA CCT AGA AGA
 I   Q   L   V   Q   S   G   A   E   V   K   K   P   G   S   S>

530         540         550         560         570
 *           *           *           *           *
GTG AAG GTG TCT TGT AAG GCA TCT GGA TAC ACC TTC ACC GAC TAC TAC
CAC TTC CAC AGA ACA TTC CGT AGA CCT ATG TGG AAG TGG CTG ATG ATG
 V   K   V   S   C   K   A   S   G   Y   T   F   T   D   Y   Y>

  580         590         600         610         620
   *           *           *           *           *
ATT AAT TGG ATG AGA CAG GCA CCT GGA CAG GGA CTC GAG TGG ATT GGA
TAA TTA ACC TAC TCT GTC CGT GGA CCT GTC CCT GAG CTC ACC TAA CCT
 I   N   W   M   R   Q   A   P   G   Q   G   L   E   W   I   G>

    630         640         650         660         670
     *           *           *           *           *
TGG ATT GAC CCT GGA TCT GGA AAT ACA AAG TAC AAT GAG AAG TTC AAG
ACC TAA CTG GGA CCT AGA CCT TTA TGT TTC ATG TTA CTC TTC AAG TTC
 W   I   D   P   G   S   G   N   T   K   Y   N   E   K   F   K>

      680         690         700         710         720
       *           *           *           *           *
GGA AGA GCA ACA CTG ACA GTG GAC ACA TCC ACG AAT ACC GCC TAC ATG
CCT TCT CGT TGT GAC TGT CAC CTG TGT AGG TGC TTA TGG CGG ATG TAC
 G   R   A   T   L   T   V   D   T   S   T   N   T   A   Y   M>

          730         740         750         760
           *           *           *           *
GAG CTG TCT TCT CTG AGA TCT GAG GAC ACA GCA TTC TAC TTC TGT GCA
CTC GAC AGA AGA GAC TCT AGA CTC CTG TGT CGT AAG ATG AAG ACA CGT
 E   L   S   S   L   R   S   E   D   T   A   F   Y   F   C   A>

770         780         790         800         810
 *           *           *           *           *
AGA GAG AAG ACC ACC TAC TAC TAC GCA ATG GAC TAC TGG GGA CAG GGA
TCT CTC TTC TGG TGG ATG ATG ATG CGT TAC CTG ATG ACC CCT GTC CCT
 R   E   K   T   T   Y   Y   Y   A   M   D   Y   W   G   Q   G>

  820         830         840         850         860
   *           *           *           *           *
ACA CTG GTG ACA GTG TCT TCT GCC TCA ACG AAG GGC CCG ACT AGT GAC
TGT GAC CAC TGT CAC AGA AGA CGG AGT TGC TTC CCG GGC TGA TCA CTG
 T   L   V   T   V   S   S   A   S   T   K   G   P   T   S   D>

    870         880         890         900         910
     *           *           *           *           *
AAA ACT CAC ACA TGC CCA CCG TGC CCA AAA GGG AAA CAC CTT TGT CCA
TTT TGA GTG TGT ACG GGT GGC ACG GGT TTT CCC TTT GTG GAA ACA GGT
 K   T   H   T   C   P   P   C   P   K   G   K   H   L   C   P>
```

```
        920         930         940         950         960
         *           *           *           *           *
AGT CCC CTA TTT CCC GGA CCT TCT AAG CCC TTT TGG GTG CTG GTG GTG
TCA GGG GAT AAA GGG CCT GGA AGA TTC GGG AAA ACC CAC GAC CAC CAC
 S   P   L   F   P   G   P   S   K   P   F   W   V   L   V   V>

            970         980         990        1000
             *           *           *           *
GTT GGT GGA GTC CTG GCT TGC TAT AGC TTG CTA GTA ACA GTG GCC TTT
CAA CCA CCT CAG GAC CGA ACG ATA TCG AAC GAT CAT TGT CAC CGG AAA
 V   G   G   V   L   A   C   Y   S   L   L   V   T   V   A   F>

1010        1020        1030        1040        1050
  *           *           *           *           *
ATT ATT TTC TGG GTG AGG AGT AAG AGG AGC AGG CTC CTG CAC AGT GAC
TAA TAA AAG ACC CAC TCC TCA TTC TCC TCG TCC GAG GAC GTG TCA CTG
 I   I   F   W   V   R   S   K   R   S   R   L   L   H   S   D>

  1060        1070        1080        1090        1100
    *           *           *           *           *
TAC ATG AAC ATG ACT CCC CGC CGC CCC GGG CCC ACC CGC AAG CAT TAC
ATG TAC TTG TAC TGA GGG GCG GCG GGG CCC GGG TGG GCG TTC GTA ATG
 Y   M   N   M   T   P   R   R   P   G   P   T   R   K   H   Y>

    1110        1120        1130        1140
      *           *           *           *
CAG CCC TAT GCC CCA CCA CGC GAC TTC GCA GCC TAT CGC TCC TGA
GTC GGG ATA CGG GGT GGT GCG CTG AAG CGT CGG ATA GCG AGG ACT
 Q   P   Y   A   P   P   R   D   F   A   A   Y   R   S   *
```

FIG. 9(contd.)

FIG. 10

CO-STIMULATION OF CELL LINES EXPRESSING A TCR ZETA CHIMERIC RECEPTOR WITH ANTI CD28 ANTIBODY



FIG.11
STIMULATION WITH ANTIGEN POSITIVE CELLS.MCF-7



FIG. 12

IL2 PRODUCTION IN RESPONSE TO VARIOUS STIMULI





FIG. 13
CD 28 - TCR ZETA FUSION



FIG. 14


scFv / CD8 / Zeta chimeric receptor
ScFv
CD8 hinge (part)
Zeta transmembrane
Zeta intracellular
scFV / CD8 / Zeta-CD28 chimeric receptor
ScFv
CD8 hinge (part)
Zeta transmembrane
Zeta intracellular
CD28 intracellular
scFv / CD8 / CD28 chimeric receptor
ScFv
CD8 hinge (part)
CD28 transmembrane
CD28 intracellular

FIG. 15


scFv/G1/Zeta chimeric receptor
ScFv
IgG1 hinge
hIgG1 CH2
hIgG1 CH3
Zeta transmembrane
Zeta intracellular
scFv/G1/Zeta-CD28 chimeric receptor
ScFv
IgG1 hinge
hIgG1 CH2
hIgG1 CH3
Zeta transmembrane
Zeta intracellular
CD28 intracellular


scFv/ h / CD28 chimeric receptor
ScFv
IgG1 hinge
CD28 extracellular
CD28 transmembrane
CD28 intracellular

FIG. 16


scFv/G1/CD28
chimeric receptor
ScFv
IgG1 hinge
hIgG1 CH2
hIgG1 CH3
CD28 transmembrane
CD28 intracellular
scFv/G1/CD28-
Zeta-CD28 fusion
chimeric receptor
Zeta intracellular
CD28 intracellular
scFv/G1/CD28-
Zeta fusion
chimeric receptor
ScFv
IgG1 hinge
hIgG1 CH2
hIgG1 CH3
CD28 transmembrane
CD28 intracellular
Zeta intracellular

FIG. 17


scFv/h.28/Zeta chimeric receptor
ScFv
IgG1 hinge
CD28 extracellular
Zeta transmembrane
Zeta intracellular
scFv/h.28/Zeta-CD28 fusion chimeric receptor
ScFv
IgG1 hinge
CD28 extracellular
Zeta transmembrane
Zeta intracellular
CD28 intracellular
scFv/h.28/CD28-Zeta fusion chimeric receptor
ScFv
IgG1 hinge
CD28 extracellular
CD28 transmembrane
CD28 intracellular
Zeta intracellular

FIG. 18

Surface expression of CD28-chimeras in transfected Jurakat cell lines determined by FITC-CD33 staining



FIG. 19

IL-2 production by Jurkat cell lines expressing p67-CD28 chimeras on infection with RAd160 stimulated with target cells



FIG. 20


51Cr Release Assay
Adenovirus infected CD8+ve peripheral blood lymphocytes with HL60 target cells
Construct
RAd160
RAd35
% specific 51Cr release
0
10
20
30
40
50
60
70
E:T ratio
0.1
1
10
100

DIKE, BRONSTEIN, ROBERTS & CUSHMAN, LLP
130 Water Street
Boston, Massachusetts 02109

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CELL ACTIVATION PROCESS AND REAGENTS THEREFOR

which is described and claimed in:

☐ the specification attached hereto.

☐ the specification in U.S. Application Serial Number _____, filed on _____.

☒ the specification in PCT international application Number GB96/03209 filed on _____, ~~and was amended on~~ February 23, 1996

I hereby state that I have reviewed and understand the contents of the above iden claims, as amended by any amendment referred to above. I acknowledge the duty to disc the examination of this application in accordance with Title 37, Code of Federal Regulati priority benefits under Title 35, United States Code, §119 of any foreign application(s) fc below and have also identified below any foreign application for patent or inventor's cert of the application on which priority is claimed.

CLEAR COPY OF DECLARATION

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. 119:			
Application No.	Filing Date	Country	Priority Claimed Under 35 U.S.C. 119?
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO

207	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

208	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 X C R Bell X	Signature of Inventor 202
Date: X MAY 20 1999 X	Date: 8.12.98
Signature of Inventor 203 A. Leibowitz	Signature of Inventor 204
Date: 8/12/98	Date: 8/12/98
Signature of Inventor 205	Signature of Inventor 206
Date:	Date:
Signature of Inventor 207	Signature of Inventor 208
Date:	Date:

Boston, Massachusetts 02109

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CELL ACTIVATION PROCESS AND REAGENTS THEREFOR

which is described and claimed in:

☐ the specification attached hereto,

☐ the specification in U.S. Application Serial Number _____, filed on _____.

☒ the specification in PCT international application Number GB96/03209 filed on _____ and was amended on February 23, 1996

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. 119:			
Application No.	Filing Date	Country	Priority Claimed Under 35 U.S.C. 119?
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO
			☐YES ☐NO

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S. Benefit Under 35 U.S.C. §120				
U.S. Applications		Status (Check One)		
Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned
PCT Applications Designating the U.S.				
Application No.	Filing Date	U.S. Serial No. Assigned		
PCT/GB96/03209	February 23, 1996			X

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (35 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Applicant	Provisional Application Number	Filing Date

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Sewall P. Bronstein (Reg. No. 16,919)
David G. Conlin (Reg. No. 27,026)
George W. Neuner (Reg. No. 26,964)
Ernest V. Linek (Reg. No. 29,872)
Linda M. Buckley (Reg. No. 31,003) David S. Resnick (Reg. No. 34,235)
Ronald L. Eisenstein (Reg. No. 30,628) Peter F. Corless (Reg. No. 33,860)
Henry D. Pahl, Jr. (Reg. No. 20,096)
Peter J. Manus (Reg. No. 26,766)

SEND CORRESPONDENCE TO:	DIRECT TELEPHONE CALLS TO:
Dike, Bronstein, Roberts & Cushman, LLP 130 Water Street Boston, Massachusetts 02109	(617) 523-3400

1 0 7	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

1 0 8	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 C.R. Bobst	Signature of Inventor 202
Date: 12 MAY 199	Date: 8.12.98
Signature of Inventor 203	Signature of Inventor 204
Date: 8/12/98	Date: 8/12/98
Signature of Inventor 205	Signature of Inventor 206
Date:	Date:
Signature of Inventor 207	Signature of Inventor 208
Date:	Date:

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Applications or PCT International Applications Designating the U.S-Benefit Under 35 U.S.C. §120				
U.S. Applications		Status (Check One)		
Application Serial No.	U.S. Filing Date	Patented	Pending	Abandoned
PCT Applications Designating the U.S.				
Application No.	Filing Date	U.S. Serial No. Assigned		
PCT/GB96/03209	February 23, 1996			X

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. § 119(e))

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Applicant	Provisional Application Number	Filing Date

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Sewall P. Bronstein (Reg. No. 16,919)
David G. Conlin (Reg. No. 27,026)
George W. Neuner (Reg. No. 26,964)
Ernest V. Linek (Reg. No. 29,822)

Linda M. Buckley(Reg. No. 31,003)David S. Resnick(Reg. No. 34,235)
Ronald I. Eisenstein(Reg. No. 30,628)Peter F. Corless(Reg. No. 33,860)
Henry D. Pahl, Jr.(Reg. No. 20,438)
Peter J. Manus(Reg. No. 26,766)

SEND CORRESPONDENCE TO:	DIRECT TELEPHONE CALLS TO:
Dike, Bronstein, Roberts & Cushman, LLP 130 Water Street Boston, Massachusetts 02109	(617) 523-3400

201	FULL NAME OF INVENTOR	LAST NAME BEBBINGTON	FIRST NAME CHRISTOPHER	MIDDLE NAME ROBERT
	RESIDENCE & CITIZENSHIP	CITY BERRY COTTAGE, WESTBROOK, BOXFORD, NEWBURY, BERKSHIRE, RG20, 8JD.	STATE OR FOREIGN COUNTRY GBX U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS BERRY COTTAGE, WESTFORD, BOXFORD,	CITY NEWBURY, BERKSHIRE,	STATE OR COUNTRY AND ZIP CODE RG20 8JD, U.K.

202	FULL NAME OF INVENTOR	LAST NAME LAWSON	FIRST NAME ALASTAIR	MIDDLE NAME DAVID GRIFFITHS
	RESIDENCE & CITIZENSHIP	CITY HOLDEN FARM, CHERITON, ALRESFORD, HANTS, SO24 ONX.	STATE OR FOREIGN COUNTRY GBX U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS HOLDEN FARM, CHERITON, ALRESFORD,	CITY HANTS,	STATE OR COUNTRY AND ZIP CODE SO24 ONX, U.K.

203	FULL NAME OF INVENTOR	LAST NAME WEIR	FIRST NAME ANDREW	MIDDLE NAME NEIL, CHARLES
	RESIDENCE & CITIZENSHIP	CITY 7, WILLOW DRIVE, TWYFORD, ~~BERKSHIRE~~ RG10 9DD	STATE OR FOREIGN COUNTRY GBX U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 7, WILLOW DRIVE TWYFORD,	CITY BERKSHIRE	STATE OR COUNTRY AND ZIP CODE RG10 9DD, U.K.

204	FULL NAME OF INVENTOR	LAST NAME FINNEY	FIRST NAME HELENE	MIDDLE NAME MARGARET
	RESIDENCE & CITIZENSHIP	CITY 64 CLARE ROAD, MAIDENHEAD. GBX	STATE OR FOREIGN COUNTRY BERKSHIRE SL64DQ, U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 64 CLARE ROAD, MAIDENHEAD,	CITY BERKSHIRE,	STATE OR COUNTRY AND ZIP CODE SL6 4DQ, U.K

205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE

201	FULL NAME OF INVENTOR	LAST NAME HEBBINGTON	FIRST NAME CHRISTOPHER	MIDDLE NAME ROBERT
	RESIDENCE & CITIZENSHIP	CITY BERRY COTTAGE, WESTBROOK, BOXFORD, NEWBURY, BERKSHIRE, RG20, 8JD. GBX	STATE OR FOREIGN COUNTRY U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS BERRY COTTAGE, WESTFORD, BOXFORD,	CITY NEWBURY, BERKSHIRE,	STATE OR COUNTRY AND ZIP CODE RG20 8JD, U.K.
202	FULL NAME OF INVENTOR	LAST NAME LARSON	FIRST NAME ALASTAIR	MIDDLE NAME DAVID GRIFFITHS
	RESIDENCE & CITIZENSHIP	CITY HOLDEN FARM, CHERITON, ALRESFORD, HANTS, SO24 ONX.	STATE OR FOREIGN COUNTRY GBX U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS HOLDEN FARM, CHERITON, ALRESFORD,	CITY HANTS,	STATE OR COUNTRY AND ZIP CODE SO24 ONX, U.K.
203	FULL NAME OF INVENTOR	LAST NAME WEIR	FIRST NAME ANDREW	MIDDLE NAME NEIL, CHARLES
	RESIDENCE & CITIZENSHIP	CITY 7, WILLOW DRIVE, TWYFORD, ~~BERKSHIRE~~ RG10 9DD	STATE OR FOREIGN COUNTRY GBX U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 7, WILLOW DRIVE TWYFORD,	CITY BERKSHIRE	STATE OR COUNTRY AND ZIP CODE RG10 9DD, U.K.
204	FULL NAME OF INVENTOR	LAST NAME FINNEY	FIRST NAME HELENE	MIDDLE NAME MARGARET
	RESIDENCE & CITIZENSHIP	CITY 64 CLARE ROAD, MAIDENHEAD, GBX	STATE OR FOREIGN COUNTRY BERKSHIRE SL64DQ, U.K.	COUNTRY OF CITIZENSHIP UK
	POST OFFICE ADDRESS	POST OFFICE ADDRESS 64 CLARE ROAD, MAIDENHEAD,	CITY BERKSHIRE,	STATE OR COUNTRY AND ZIP CODE SL6 4DQ, U.K
205	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
206	FULL NAME OF INVENTOR	LAST NAME	FIRST NAME	MIDDLE NAME
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE